integrated report year ended december n h significance corporate symbol symbolic representation otsuka groups corporate philosophy corporate symbol adopts initial corporate name motif representing sky large rendered grada tions otsuka blue small otsuka red represents focused energy otsuka wellspring tenets offsetting two forms poised balance otsuka name spelled open friendly typeface corporate symbol conveys otsuka groups energetic commitment human happiness good healththe challenging spirit innovative creative handed manufacturing began years ago original otsuka company established manufac otsuka group companies created whole range products otsuka turer raw chemical materials using bittern famous salt pans naruto tokushima provide pioneered market new products pocari sweat prefecture japan founder busaburo otsuka born although said health drink provides unprecedented value oral anticancer agents antipsychotics busaburo far land average farmer time wanted start busi unique action mechanisms equolcontaining food equelle promote ness aim making great strides turning thoughts industry spirit womens health beauty handed day backdrop steady business diversification includ continue provide new products solutions contribute health ing entry iv solutions business nationwide global expansion many people around world innovative creative manufacturing decisions always challenging spirit otsuka boldly sought unknown satisfied status quo mean creative products services wont produced continue seek challenges free preconceptions secondgeneration president founder masahito otsuka busaburo otsuka otsuka holdings co ltd integrated report challenging see otsukas things end antituberculosis drug deltyba aquaretic adpkd treatment drug samscajinarcjynarque widely used around world grit brought market many years difficult research development equelle also supports womens health beauty developed years research soybeans aim creating new markets took long time value longpopular oro namin c drink calorie mate recognized otsuka determination always persistently challenged even unknown fields starting something resolving get results end corporate culture nurtured many years handed every one approximately employees working countries regions around world brand name adpkd treatment multiple regions outside japan brand name adpkd treatment us otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report ot suka originality contributing health total healthcare company based enduring mission contribute health people worldwide otsuka advancing pharmaceutical business diagnosis treat ment diseases nutraceutical business helps people maintain improve daytoday health strive establish altogether new markets first developing products grounded sciencenot pharmaceuticals also nutraceuticals including func tional foods drinks persistently infor matively communicate novel value products otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report integrated report beginning fiscal edition otsuka holdings combined annual report csr report single integrated report corporate philosophy brings together financial information nonfinancial information hope deepen stakeholders understanding groups aim become indispensable contributor peoples health worldwide producing report referred interna tional integrated reporting framework advocated international integrated reporting council iirc guidance collabo rative value creation developed japans ministry economy trade industry reporting period precautions regarding forwardlooking statements fiscal january december integrated report summarizes operating financial results otsuka holdings information january included co ltd subsidiaries fiscal january december also keeping corporate philosophy otsuka mottos jissho actualization sozosei creativity includes information regarding selected material events occurred january scope reporting date publication report contains forwardlooking statements pertaining otsuka group strives pursue achieve otsuka group supports lives people worldwide principle report covers otsuka holdings co ltd subsidiaries activities plans projections strategies prospects otsuka group companies wide range innovative creative products including pharmaceuticals functional beverages func data restricted scope noted report statements based upon current analysis belief light information available issuing date report actual results may therefore differ due risks tional foods dedicated cultivating culture dynamic corporate climate reflecting vision health reference guidelines uncertainties may affect otsuka group operations care company finding ways live harmony local communities natural environment global gn rte r sn ta nio dn aa rdl sintegrated reporting framework iirc medical information perspective contributing affluent healthier lives people iso integrated report unified brand name used product different brand environmental reporting guidelines edition moe names different countries regions sake readability therefore products guidance collaborative value creation meti etc may available countries may available different brand names different indications different dosages strengths please note information regarding pharmaceutical products including products development intended kind advertising promotion medical advice otsukas goal become indispensable contributor c n e n peoples health worldwide otsuka group operates business goal becoming indispensable contributor peoples health world wide fulfilling corporate philosophy every activity operations encompass two core businesses pharma ceutical business provides comprehensive health support diagnosis treatment diseases nutraceutical business helps people maintain improve daytoday health endeavor create message feature value creation unchanging value improving peoples health worldwide continue provide value society president section nutraceuticalsnutrition pharmaceuticals message president access medicine growth trajectory review second mediumterm fight tuberculosis seeking provide value management plan old disease new face business essence management outline third mediumterm value creation model management plan financial highlights nonfinancial highlights sozosei resisting urge copy pursuing creativity otsuka capable delivering business strategy foundation data section jissho seifactualization section value creation achievement completion actualization discovery truth research development otsuka group csr main data pharmaceutical business society management discussion analysis nutraceutical business environment consolidated financial results fiscal ryukan godo process discovering consumer products business governance core substance something businesses directors audit supervisory board consolidated financial statements sweat recognize hard work members group structure overview main way practice operating companies global network c orporate informationshareholder information otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report message president message president business model goals new innovations unique business model tatsuo higuchi president representative director ceo otsuka holdings co ltd business model healthcare environment characterized expanding medical costs due aging societies including medication costs chronic illnesses dementia cancer publichealth need address treatmentresistant emerging infectious diseases emergence new lifechanging health technologies partly response developments penetration generic drugs reforms drug pricing systems proceeded increasing speed mean people growing interested daily disease prevention measures based lifestyle modifications areas nutrition exercise rest based mission contribute health people worldwide otsuka groups activities based two pillars pharmaceutical business extends diagnosis treatment diseases nutraceutical business helps people maintain improve daytoday health business model based belief healthcare wholebody phenomenon fully actualized continue provide innovative products services meet demands times including lifestyles evolutions noted therefore seek synergies collaborations across multiple group companies drive innovation creation new markets believe distinctive approach position us make tangible contributions resolution healthrelated social challenges well creating new value pharmaceutical nutraceutical global total healthcare business business diagnosis maintaining treatment diseases improving daytoday company health embracing challenges based enduring mission innovation derived synergies core brands nutraceutical businesspocari sweat calorie matewere born perspectives technologies knowhow gained clinical nutrition business based motto mission otsuka people creating new products better health world engaged since simultaneously expanding medical device business lever wide otsuka group works hard create innovative products order meet universal age otsukas strengths pharmaceuticals exploit new paths total healthcare diverse business portfolio foods beverage pharmaceuticals addresses wholebody health aspiration people around world stay healthy end constantly ask pharmaceutical business various group companies foster flexible groupwide strate put practice otsuka achieve contributing society also core gies decision making nutraceutical business group companies share information tenet management help realize sustainable one continue global committee global health issues consumer expectations businesses generate firstandonly innova nutraceutical business embrace challenges based mission without swept currents moment tions unique approaches seek leverage otsukas soft hard assets across group companies soft assets include corporate culture philosophy well deep ingrained knowledge based nearly year history committed workforce pas sionate aims hard assets include advanced technologies infrastructure span ning globe otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report message president selfactualization discovery truth achievement completion case indispensable contributor peoples health worldwide pharmaceuticals jissho actualization occurs drug approved reaches business environment undergoing significant changes impact patient sozosei term used akihiko otsuka thirdgeneration leader group changes include advances basic science influence diseasetreatment systems profusion companies based determination pursue otsuka achieve without imita information data broad societal evolutions peoples expectations tion underscores policy creating innovative products defy existing preconceptions ryukan godo calligraphic work otsuka lifestyles social circumstances founder busaburo otsuka shifting context many things otsuka achieve example digital technology data information open opportunity deeper insights areas diseases treatments affect individual patients consumers balance consider realizing ryukan godo jissho sozosei ations product flavor healthiness however obligates us use insights responsi policy use hands sweat find essence solutions without imita bly behalf society well company also protect individual privacy tionto develop launch secure products market deploying otsukas uncommon management style principles continue deliver example samscajinarcjynarque revolutionary aquaretic agent took years sustainable growth help address healthcare challenges quest become indis develop resulted research began physicians request want diuretic pensable contributor peoples health worldwide excretes water many years hard work samscajinarcjynarque made avail able patients worlds first treatment autosomal dominant polycystic kidney disease adpkd inherited disease therapeutic treatments monument engraved corporate nutraceuticals area pocari sweat developed beverage easily replenish philosophy tokushima prefecture japan water electrolytes ions lost sweating launched japan one otsuka values beverages broke established market preconceptions sold unusual bluecolored relatively light taste time took gain accep distinctive corporate culture cul tance consumers emphasize value new drink employees conducted sampling sessions help consumers experience effect result meticulous efforts tivated many years firmly established brand created completely new ion drink market japan outcomes mediumterm management plan nucleus corporate culture foundation otsuka groups business corporate culture three important princi overview overview second mediumterm second mediumterm ples culture ryukan godo commitment jissho actualization sozosei creativity management plan management plan ryukan godo term coined busaburo otsuka founder otsuka group p means one discover core substance truth matters hard work practice jissho main principle conveyed masahito otsuka secondgeneration leader diversify revenue structure achieve sustainable growth first mediumterm management plan fiscal maximized value antipsychotic agent abilify second mediumterm management plan fiscal abilify patent expired determined important priority diversification revenue structure therefore plan period strength ened broadened businesses revenue pillars built foundation support groups sustainable growth second mediumterm management plan outcomes issues pharmaceutical business sought reinforce therapeutic franchises enjoyed steady growth newer global products including abilify maintena rexulti samscajinarcjynarque result rebuilt robust revenue foundation made signifi cant progress toward maximization investment cash flows growing core otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report message president businesses nutraceutical business made reforms consistently delivered oper human resources sought otsuka ating profit margin ten percent higher thanks efforts achieved objective people embrace challenges rejuvenate product portfolio moving business toward sustainable growth hand also encountered number hurdles business environ determination ment japan become challenging due dramatic reforms drug pricing system steppedup measures promote use generic drugs addition creating many entirely new drug offerings areas therapeutic precedent market jynarque abilify mycite firstever digital medicine development commercialization pro cesses unprecedented products light challenges respecting diversity believe key priority maximize corporate value anticipating major changes taking otsuka group consists companies around employees worldwide place business environment half overseas employees aim company diverse employ ees excel regardless nationality differences requires corporate culture employees feel fulfillment finding new values mutual acknowledgment active acceptance different backgrounds mindsets traditions well occasional clash outline outline third mediumterm management plan differing perspectives otsuka embraced diversity since concept third mediumterm third mediumterm management plan period advance taken hold japan elsewhere actively utilized diversity human resources management plan grow global market total healthcare company p focus maximization existing business value expansion global prod ucts abilify maintena rexulti samscajinarcjynarque lonsurf formed strong basis second mediumterm management plan encouraging challenges addition create new value challenging new modalities categories otsuka embedded culture based taking challengesdoing com geographies contingent regulatory approvals latestage candidates new therapeutic panies choose fact nobody else tried something type chal areas become revenue drivers avanir pharmaceuticals avp development several lenge need use invigorate organization starting scratch need mental health disorders vadadustat development anemia secondary chronic kidney consider proceed form hypothesis move action started disease collaboration akebia therapeutics nutraceutical business aim work sticky resolve end believe approach leads us subsequent challenges grow nature made line leading supplements sector vitamin products tailored also growth needs individual consumers daiya foods portfolio delicious plantbased foods willing embrace challenges otsuka provides culture active support first expand product line distribution channels appeal millennial consumers responsibility people given responsibility feel much committed investments future growth balanced disciplined focus profit margins responsible accumulation experiences results personal threfore shareholder returns development third mediumterm management plan period time sustainable growth seeds planted second mediumterm management plan period sprout become large trees develop executives lead company ceo one personal areas focus development executive human resources lead company future business management equates people work aspiration people dont grow otsuka celebrate th anniversary order grow creatively become indispensable contributor sustainably next years believe cultivation human resources especially peoples health worldwide nextgeneration leadership extremely importanton par making medium longterm capital investment reason otsuka holdings opened otsuka global academy con nth ducts executive human resource development programs based swiftly identifying mediumterm third management fostering future leaders turn support development employees mediumterm plan specifically three programs otsuka group employeesthe senior leadership pro second management gram middle leadership program global leadership program uppermid mediumterm plan first mediumterm management dle level managers otsuka group companies around world employees mana pg lae nment plan participated date programs convey latest managerial knowledge skills also emphasize continuity relevance business approaches practiced successfully since founding includes managerial leadership styles successive generations otsuka leaders perceived business case studies successes failures otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report message president define csr broad sense integrated part business dont pro mote sustainability along businesses pharmaceutical nutraceuti cal products created produced help people maintain improve health realize better life aim simultaneously achieve sustainable growth healthy sustainable society enabling access products deltyba mentioned constantly pursue activi ties aimed contributing ways otsuka november otsuka holdings became signatory united nations global com pact signatory express support global compacts ideals time helping achieve sustainable development goals sdgs adopted united nations summit way reaffirm otsuka groups commitment working society order achieve sustainable development executive human resource development program risk preparedness discussions also center type qualifications human resources required leadership preparing risk also important sustainable corporate growth healthcare company effective decisionmaking methods involved peoples lives product quality essential business work continuously academy place participants feel learn directly discus maintain improve quality throughout value chain mind otsuka pharma sions hope participant completes program understanding otsukas true ceutical made quality assurance department independent production department nature sense ownership reflected work also want participants headed executive directorlevel leader convey felt learned academy fellow employees also hold global product quality meetings around participants including man time young employee otsuka often asked agers heads quality control meet discuss quality issues futureoriented initiatives value company result learning many things predecessors come addition conducting internal audits plant regularly strive ensure reliability find answers teacher training programs pass findings data specifically introduced computer system prevent important documents employees age struggling answer question data related quality production falsified spent month human resource development including preparation maintain improve compliancerelated awareness employees around time traveling many things still learn thinking engaging world produced universal training materials conform otsuka groups global younger colleagues serious discussions business based multiple perspectives code business ethics global anticorruption policy employees attend training want continue teach learn hand hand lead company annually compliance violations profound impact survival company reason promote continuous global measures ensure every employee engages work based high ethical standards consider otsukas biggest risk would forget roots without deep stead fast roots trees grow large must go daily activities without csr activities integrated businesses forgetting learn three important principles corporate culture ryukan godo commitment sweat recognize way jissho actualization sozosei creativity pursuing contributions csr p otsuka make help realize sustainable society adhering corporate philosophy help realize sustainable society deltyba one worlds first new antituberculosis drugs years used coun tries worldwide today addressing drugresistant tuberculosis serious public health problem especially areas inadequate health systems otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report message president review active rd investment core therapeutic areas second mediumterm management plan strengthened product franchises core therapeutic areas sustainable growth plan continued active investments rd working strengthen drug discovery capabilities maximize value new product lineup drives growth focus core therapeutic areas time invested outside projects establishing diversified revenue structure achieve sus would bring synergies existing knowhow intellectual assets enhanced development pipeline combining efforts moved rd activities forward ensuring future sustainable growth contributing social issues tainable growth psychiatry neurology oncology cardiovascular renal second mediumterm management plan hereinafter referred plan fiscal final fullscale entry neurologic area established groupwide drug discovery developed nextgeneration core year sets highest priority diversifying groups revenue structure achieve sustainable growth strengthening psychiatric area platform introduced new therapeu area tic technologies pharmaceutical business pursued strengthening core therapeutic franchises nutraceutical fullscale entry area neurol licensed vadadustat drug ogy acquisition avanir strengthened inhouse drug discov development renal anemia business hereinafter referred nc business pursued business transformation structural pharmaceuticals ery capabilities akebia therapeutics reform achieve growth final year first final year second h afac fvq ee cu ti c ri peti bao e f c nl un nic ta al p pe ev de l mop rke en f oca r p pa sb euili dti oe bs uth lba r c p pot h hr l ae la r rn mbg rh c cae e etn u uioe tn id c c si l lyn ss te ner dmg r co se tu n ep x e rr eu dg ni tc ao ihve thnc rdq u uki gir de hnd ae cyn q dt ui ib iseo itad oy e n p r oela flat f vto e isr dm ep rt rpe ac eh linn eo logy establishing diversified mediumterm management plan mediumterm management plan agc iq tau ti ir oe nd aa p soro cd iau tect u wn id r lze hve el io mp em rsent avp rigcq hu tsi r ie nd se iav e fl oo rp ne dt ea nn od im nea r rk ee ct ei pn tg r e bx sia nn ed ssed global investment medical device expansion cns business merger antagonist arcus biosciences acquired ultrasound renal denerva revenue structure fy fy otsukas assets psychiatric area business entry genetically modified cell therapy tion treatment device technology licensed fremanezumab japan platform acquisition recor prophylactic migraine drug candidate signed joint development exclu medical facing end exclusive sales period teva pharmaceutical industries thiv ee gsa el ne es tc ho en rt ar pac yt w ruit gh nk ya r ea obi acquired arterial stent business founda consumer products worlds first digital medicine system sitcr cd car japan tion cuttingedge products abilify groups main product business abilify mycite approved us acquisition veryan medical businesses central neurological obtained exclusive development pursued diversifying revenue structure excluding abilify ac dq hu dir e td h en rae pu ero uv tia cn dc ee v en lod p mb et nai tn de rd u g woan rlu df wa ic dt eu r fi rg man md g r k ce ati rn g r cig elh l ts achieve sustainable growth investing abilify centanafadine therapy osaka university nutraceutical aggressively growth making strategic business oncology alliances business area grown steadily cardiovascular led new product lines result renal nc business achieved top priority diversifying sales pharmaceuticals earnings structure improved profitability revenue bn revenue bn nc business pursued fundamental reforms operating profit nutraceutical business jgaap ifrs business practices reviewing business assets revenue revenue external customers second mediumterm implementation two strategies accelerating management plan billion operating profit pharmaceutical business global expansion developing new products operating profit margin reviewed business practice based various value chains focused development ingenious new maximizing product value products contributing extension healthy life expec tancy improvement product value utilizing scientific achieved target sales revenue new product lines evidences experience cultivated pharmaceuticals promotional activities helping customers recognize building foundation continue drive groups regrowth health benefits products also accelerated global expansion core brands including pocari sweat plan categorized antipsychotic agent revenue new products global expansion results oronamin c drink entered plantbased longacting injectable abilify maintena antipsychotic business acquisition daiya foods agent rexulti vreceptor antagonist samscajinarc bn jgaap ifrs jynarque global products anticancer b lli n c h e e n r te e f f ort hth ee dg oro f u scp h h ea ds u lec h ai ne dv e ed ta b lo isp er da bg u sina erg ssin rf u co tv ue rr e trau ne ito io n c ah l pn eg rie din c oh e rc ino gn hl eid nat ine ed mfis oc na tl hy se frr f mis c aa pl r il e dn ed ce ed ec b e r agent lonsurf nextgeneration product new necessary constantly maintain level operating margin drugs launched japan domestic new prod ucts considered growth drivers accelerating global expansion plan period actively invested management resources approvals addition new indications expansion sales areas early maximization asia north america europe product values pocari sweat plantbased foods nutrition sant result total revenue new product lines established subsidiaries thailand entered plantbased food sector acquiring daiya foods strengthened fiscal increased billion yen rd p nhi alip mpi ne c rtr ie nn kg sales nutritional supplements p foro r fu rec eti frn mys tem initial target billion yen successfully estab global products nextgeneration products new drugs japan started local production sales entered natural foods channel acquisition foodstate products indonesia lished foundation strongly drive groups due change consolidated fiscal year fiscal ended december soyjoy equelle transitional period covering nine months april december started local production indonesia started roll us market regrowth plan otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report message president outline third mediumterm management plan business strategy maximizing existing business value new value creation otsuka enhance strategic initiatives upon designating following products brands growth drivers namely four global prod ucts pharmaceuticals abilify maintena rexulti samscajinarcjynarque lonsurf three major brands pocari sweat advance global market unique nature made nutrition sant three nurture brands nc business daiya foods equelle bodymaint additionally otsuka launch nurture new product lines drive sustainable growth pharmaceutical nc businesses total healthcare company growth drivers revenue forecast pharma new product lines bn fiveyear growth phase product lines scheduled launched bn corporate philosophy otsukapeople creating new products better health worldwide pharma global products practice management spirits ryukangodo commitment jissho actualization sozosei cre abilify maintena samscajinarcjynarque ativity following philosophy spirits otsuka creating new values engaging various rexulti lonsurf approx unique business identifying true insight needs around world creating new concepts products effec bn e tively combining science technology mixing various existing businesses spinouts pioneering bn nc nurture brands untouched niche areas define third mediumterm management plan fiveyear period growth daiya foods bodymaint establishing unique total healthcare company global market focusing core equelle businesses pharmaceutical nutraceutical going maximize values existing business create e new values practicing business management corporate wide awareness capital costs bn nc major brands pocari sweat nutrition sant nature made e e e e e e e e e e performance targets rd mtm plan th mtm plan business profit cagr growth strategy helped organic growth existing businesses pharma key performance targets billion maximize values existing businesses ceutical nc businesses plan sales revenue e e cagr pharmaceutical challenge new frontiers otsuka reach billion yen fiscal final year plan ae business generate innovation creative diverse research platforms revenue increase billion yen business prof rd expenses reach billion yen b ru din ee xs ps ep nro sefi st nutraceutical create new concepts keeping eye changes environments challenge new categories new areas record highs target business profit fiscal ratiorevenue business continuous high profit structure set billion yen cagr addition rd expenses continue actively invest research development business profit sustainable growth ratiorevenue financial policy roe note exchange rate assumptions euro business management corporatewide awareness including performance growth strategic investments etc business profit revenue cogs sga share profit associates rd expenses capital costs revenue plan organic growth e otsuka going implement business management awareness capital costs reflecting business bn bn corporatewide awareness capital costs midterm risks period promote throughout group performance assessments taking account capital costs business strategic investing otsuka work bn improve return invested capital roic medium roic improvement optimal financing midlong term basis longterm time horizon monitoring roic actively return business capital cost bn investing new value creation maximize pharmaceutical business investment financial policy bn business gi rn wfin tha n inc vin eg st mc eti nv tit si e ws h ilet cu ok na iw deill r ne gc u thre e n oe pc te imss aa lr c af pu tad ls strat ogi ie cs management stp ruti cm tua rl e capital co vrp ao lur eate maximize existing business value structure active investment efforts aim maximize corporate create new value nc business bn value bn consumer businesses presentation materials third mediumterm management plan available otsuka holdings website httpswwwotsukacomenirlibrarypresentationhtml e e e e e revenue external customers otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report feature access medicine access medicine sdgs target end epidemics hivaids tuberculosis malaria feature neglected tropical diseases combat hepatitis water borne infections commu nicable diseases fight tuberculosis number individuals infected annual deaths mycobacterium tuberculosis tuberculosis old disease new face global public health improved thanks deltyba tuberculosis drug approx billion approx million united nations un millennium development goals mdgs adopted among mdgs goal combat hiv aids made great progress un announced sustainable development goals sdgs inherit ideals tuberculosis still spreading limitations conventional medici mdgs embarked new initiatives achieve goals worldwide nal treatment deploying tuberculosis drug deltyba otsuka group seek ing eliminate tuberculosis listed target sdgs tuberculosis still spreading worldwide tuberculosis one currently multiple drugs used treat tuberculosis also contribute improvement global public health worlds top three infectious diseases along malaria one drug administered bacteria become resistant hivaids approximately million people develop tuberculosis treatment usually involves administering three four drugs year around million die making lead cases drugsensitive tuberculosis successfully ing cause death among infectious diseases moreover tuber treated firstline drugs proper case management culosis highly contagious billion people said recent years however emergence resistance tubercu infected mycobacterium tuberculosis mtb bacteria losis drugs become widespread discontinuation medica global population billion tion reason irregular doses side effects mtb may develop active tuberculosis disease gives rise bacteria resistant drugs stubborn bacterium patients contracted taken among multidrugresistant tuberculosis disease must continue taking multiple medications combi mdrtb bacteria become resistant rifampicin nation sometimes six months due drugresistant isoniazid two potent firstline therapeutic agents strains tb prevalent many low middleincome coun extensively drugresistant tuberculosis xdrtb resistant tries lowresource settings tuberculosis requires even greater number drugs representing major global longterm treatment represents major economic challenge challenge campaign control disease highburden countries global tuberculosis report global distribution tuberculosis patients tuberculosis airborne infectious disease tuberculosis mycobacteria enter body data multiply mainly lungs resulting symptoms coughing production applicable sputum serious cases infection cause breathing difficulties affect organs potentially resulting death highly contagious disease takes hold cases may develop several years reference global tuberculosis report infection due weakening immune system otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report feature access medicine deltyba improving global health one first new external drugs years collaborations birth deltyba expanding access tuberculosis drugs deltyba supply route via st p bgdf lowincome countries collabora nobody otsuka must wholly owned tion stop tb partnerships subsidiary otsuka pharmaceutical deltyba received approval treatment mdrtb drugs according report published treatment global drug facility stoptbgdf completely different mechanism action com action group tag patient advocacy group combating otsuka order pared previous therapeutic agents also effective hivaids tuberculosis otsuka pharmaceutical larg deltyba one first new tuberculosis drugs approved novel programs gdf tuberculosis bacteria become resistant exist est private funder tb research development last years meaningless drug acces products ing drugs therefore expected play role therapeutic sible patients said many tuberculosis patients gmbh drug mdrtb becoming serious developing countries africa asia regions delivery deltyba included model list essential top ten funders tb research otsuka group business base reason edi dci en le ts bli ast io f p nr eio ori ft th er u ng es w en n tuy bc eo ru cn ut lory drugs approved orf gu nd izi tg ion sector total usd perc fe un nt inf gtotal w fae c ib lite yg sn w po tbrk gin dg fw ah n oh g nto izp tt ib np dr et dn ie cr th ei dp og elo xb pa al n dir nu gg pharo mt asu cek ua ical gdfs supply agency order programs world last years although mdrtb currently us nih public access qualityassured tuberculosis drugs diagnostic delivery gaining prominent attention tuberculosis research regarded bill melinda gates agents ensuring sustainable procurement drugs philanthropic foundation fashion pharmaceutical industry recently developing countries stoptbgdf supplies deltyba government agencies relevant ngos countries earmarked usaid public rifampicin discovered countries patients cur support global funds unitaid multilateral thought tuberculosis become treatable disease rently taking drug receive medicines procured delivery many researchers research institutes around otsuka private stoptbgdf highlighting organizations excellent contribu pharmaceuticals world stopped development otsuka company tion expanding access medical institutionpatient uk dfid public continue research based belief tuberculosis founded stop tb partnership mission serve every person vulnera company x private ble tuberculosis ensure highquality diagnosis treatment care available serious global health problem must continue need stoptbgdf largest global provider qualityassured antituberculo european commission public research nobody else deltyba created sis medicines diagnostics laboratory supplies public sector also providing us cdc public technical assistance tb programs supporting wide use innovative tools years research activities otsuka pharma ceutical remains actively engaged rd new tuberculosis edctp public topics cooperation japa deltyba research history nese government rifampicin discovered standard treatment tuberculosis deltyba also cooperate receive otsuka pharmaceutical commenced drug discovery research work infectious disease one key themes support japanese govern fullscale research tuberculosis drugs started ment various ways include clinical trials started opc later deltyba treatment tuberculosis support access initiatives deltyba approved launched europe japan therapeutic drug multidrugresistant tuberculosis mdrtb seas sharing educational infor deltyba added model list essential medicines mation international conferences one eight items economic cooperation plan united nations general assembly highlevel meeting agreed japanese russian leaders improving tuberculosis held new york city september agreement concluded stop tb partnerships global drug facility gdf events medical care promoting healthy life spans katsunobu kato minister health labour eastern economic forum held vladivostok september welfare gave speech developing treatments licensing agreement executed rpharm russia manufacture commercialization deltyba russian federation japans prime minister shinzo abe made speech multidrugresistant tuberculosis japan contributing surrounding countries mutual cooperation aimed getting swift approval eradication disease worldwide deltyba russia speech said fight time adopted political declaration toward eliminating licensing agreement executed mylan india expand deltyba approval commercialization activities highburden tuberculosis japan russia joined hands tuberculosis countries otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report deltyba improving global health value eessttaabblliisshhiinngg aa ssuuppppllyy nneettwwoorrkk wwhhiicchh creation wwiillll ssaavvee ppaattiieennttss aarroouunndd tthhee wwoorrlldd section expanding access patients n terview worldwide growth trajectory numerous collaborations formed combat tubercu indispensable company global health losis diseases threaten global health eeking provide value rd institutes conduct unique research united nations various national governments business imitate companies pursue provide active support addition aforementioned otsuka deltyba embodiment v alue creation model cooperation gdf otsuka pharmaceutical contributes efforts tuberculosis serious global health health people around world various collaborative financial highlights problem approach problemthe belief initiatives many stakeholders include partici somebody must keep confronting disease nonfinancial highlights pation global health innovative technology fund ghit remained unchanged even japanese publicprivate partnership established address infec years since otsuka initiated research based tious diseases worldwide well cooperation programs corporate philosophy otsukapeople creating new spearheaded mdecins sans frontiresdoctors without bor products better health worldwide con ders msf also obtained support bill tinue working external stakeholders benefit melinda gates foundation development new tubercu global health sense speed commitment losis treatment methods formed alliances activities continue address various global companies strengths public health issues solved globally pro operations areas business opera cess believe fulfill aim becoming tions mylan indiasouth africa rpharm russia indispensable contributor peoples health worldwide march launched new delamanid clinical access program dcap cooperation south african government aim national program give patients mdrtb swift access deltyba regulatory approval initiatives otsuka pharmaceutical working establish sustainable drug delivery systems affordable keiso yamasaki prices patients around world need deltyba otsuka pharmaceutical co ltd treated regardless socioeconomic status income level global project leader june countries expanding use tb project deltyba based multifaceted approach column nextgeneration tuberculosis drug candidate opc hiz tower otsuka pharmaceutical conducting research tuberculosis drugs follow deltyba latest development compound building pictured part called opc undergoing initial trials south africa confirm safety efficacy tokushima research institute named opc kills tuberculosis bacteria mechanism inhibits activity enzymes essen drug laid foundation otsuka groups pharmaceutical business tial synthesizing mycobacterium tuberculosis cell walls mechanism action differs completely ceramic mural wall designed existing antituberculosis drugs including deltyba expected effective treatment taro okamoto called inochi odoru various strains tb developing drug also receiving support bill melinda gates dancing life named notable tokushima writer activist jakucho foundation cited elimination tuberculosis worldwide one top priorities continue setouchi research centers otsuka engaging tb rd aim establishing innovative treatment methods pharmaceutical situated nearby otsuka holdings co ltd integrated report value creation section growth trajectory chemical raw materials pharmaceuticals beverages foods since otsuka groups founding chemical raw material manufacturer built iv solutions business spurred groups growth continued diversify operations achieve steady growth bringing market series original products oronine h ointment oronamin c drink bon curry pocari sweat calorie mate well pharmaceuticals antipsychotic agent abilify drug novel mechanism action samsca worlds first oral aquaretic drug foundation phase growth phase expansion phase started business naruto numerous unique products opened new markets diversified seeking global growth total healthcare company tokushima prefecture japan business pharmaceutical business antipsychotic agent abilifywhich first went sale us otsuka group started period group leveraged technologies knowhow cultivated available prescription roughly countries regions greatly manufacturer chemical raw materi expansion iv solutions clinical nutrition products businesses successively spawn accelerated otsuka groups global expansion even today therapeutic drugs pro als production magnesium unique core brandsthe ion supply drink pocari sweat balanced nutritional food calorie duced inhouse drug discovery program helping treat diseases worldwide carbonate derived bittern mate worlds first commercial retort pouch food product bon curry started pharmaceuticals include longacting antipsychotic agent abilify maintena new antipsy residue remains salt pans inhouse pharmaceutical rd established groups business foundation deliver total chotic agent rexulti vreceptor antagonist samscajinarcjynarque anticancer salt production business made healthcare solutions via twin business segments pharmaceuticals nutraceuticals agent lonsurf nutraceuticals business group companies addressing health issues steady progress supply broader needs different corners world example pharmavite operates nutritional range pharmacopeia raw materials supplements business mainly us nutrition sant nutritional food company europe entered iv daiya foods develops plantbased foods north america solutions business expanded nation wide launch intra venous drip solution worlds first commercially available food balanced nutritional food product retort pouch bon curry calorie mate launched lonsurf launched equelle international business development phase launched jinarc rexulti bbiilllliioonnss ooff yyeenn launched abilify maintena started aggressive global expansion quality vital factory packaging drawing advanced technological knowhow cultivated japan started manufacture market putting expand iv solutions business overseas markets cur consumers position otsuka groups guiding precept rently business companies worldwide manufacturing selling launched samsca founders handwriting expresses commitment products committed local manufacturing aim maintaining quality still serves basis otsukas improving quality think contributes local communities mainly manufacturing today form fair product pricing employment creation also began market pocari sweat overseas product sold countries regions original iv solution years experience intravenous solutions business launched abilify leading company forefront japans iv solutions industry china otsuka pharmaceutical co ltd indonesian high school students enjoy otsuka became first japanese pharmaceutical ing pocari sweat company establish joint venture china launched ts established otsuka seiyaku kogyobu launched pletaal established pharmaceutical research launched calorie mate started iv solutions business institute l u n ched pocari sweat la mu un cc oh se td launched launched first inhouse devel launched uft oronine h ointment oped pharmaceuticals mikelan meptin launched oronamin c drink launched bon curry revenue trend nutraceuticals consumer products others pharmaceuticals due change consolidated fiscal year fiscal ended december transitional period covering nine months april december otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report value creation section seeking provide value business value aim provide total otsuka group contributes peoples health worldwide creating innovative products two core businesses pharmaceutical business aims addresses unmet medical needs healthcare nutraceutical business seeks fulfill yettobe imagined consumer needs otsuka innovative products social challenges unmet medical needs diagnosis treatment pharmaceutical social challenges business yettobe imagined needs maintenance improvement daytoday health nutraceutical business otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report value creation section value creation model corporate philosophy otsukapeople creating new products better health worldwide otsuka group creates new value address universal social challenges various businesses innovative prod ucts aim provide total healthcare solutions based diverse three quintessential management principles ryukan godo sweat recognize way jissho actualization sozosei creativity repeat business underlying capital ing value creation process aim realize sustained development activities society sustained growth group total healthcare solutions human capital number employees diversity inclusion innovative diversity p products financial capital total assets sozosei billion creativity creation social value manufacturing capital jissho solving social challenges manufacturing bases actualization total healthcare underlying input ryukan godo capital intellectual capital unmet medical needs sweat recognize way solutions aim rehabilitate patients suffering rd expenses psychiatric neurological diseases pharmaceutical business comprehensive patientoriented cancer treatment billion worlds therapeutic drugs developed voice realworld clinical settings latephase development initiatives eradicate tuberculosis projects projects projects phase ii later stages p yettobe imagined needs brands helping people maintain improve health sciencebased product discovery raising peoples health awareness educational social relationship capital activities creation companies outcome social value physical mental health employees development countries regions human resources establishment value chains aimed realizing sustain able society natural capital scope otsuka holdings subsidiaries environmentally friendly manufacturing affiliated companies december otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report value creation section financial highlights due change consolidated fiscal year fiscal ended december transitional period covering nine months revenue rd expenses pharmaceutical business billion revenue overseas sales billion rd expenses pharmaceutical business rd expenses ratio ratio pharmaceutical business yoy yoy billion billion revenue grew previous year mainly due rd expenses pharmaceutical business increased growth sales growth drivers pharmaceutical previous year result active rd investments business three global products abilify maintena maximize value inhouse developed products samscajinarcjynarque rexulti new products core therapeutic areas psychiatry neurology oncology japan growing sales volume pocari sweat nutraceu cardiovascular renal system tical business also contributed revenue growth revenue rd expenses pharmaceutical business overseas sales ratio rd expenses ratio pharmaceutical business jgaap ifrs plan jgaap ifrs plan operating profit total assets billion operating profit operating profit billion total assets ratio equity attributable margin owners company total assets yoy billion billion operating profit increased previous year ratio equity attributable owners company total spite increased rd expenses onetime expenses includ assets maintained high level promoting ing impairment loss increased revenue pharmaceutical active investment enhance competitiveness business nutraceutical businesses absorbed growth well pursuing operational efficiency operating profit total assets operating profit margin ratio equity attributable owners company total assets jgaap ifrs plan jgaap ifrs profit attributable owners company dividend per share billion profit attributable owners company ratio profit attributable dividend per share dividend payout owners company ratio yoy billion profit attributable owners company decreased otsuka group considers profit distribution shareholders previous year since us tax reform resulted important management issue basic policy large reduction deferred tax liability previous year maintain stable continuous profit distribution securing excluding impact tax reform years results enough cash invest business growth prepare almost level previous year changes business environment profit attributable owners company dividend per share ratio profit attributable owners company dividend payout ratio jgaap ifrs plan jgaap ifrs plan otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report value creation section nonfinancial highlights number employees total co emissions number number employees ratio employees outside thousand tonsco ton million total co emissions japan target reduce co emissions compared thousand tonsco otsuka group strives utilize diverse human resources japan otsuka group working reduce total co emissions order adapt acceleration global business expan indonesia making efficient use energy use sion varied social needs employee ratio outside cogeneration systems renewable energy fiscal total india japan increased approximately north america co emissions increased previous year due increase production resulting acceleration south korea china global expansion europe total co emissions co emissions per sales outside japan japan scope calculated consolidated subsidiaries otsuka group compa scope otsuka holdings subsidiaries nies constitute top co emissions originating energy female manager ratio energy composition calorie conversion number female manager ratio otsuka group believes active involvement diverse human resources free open workplace environment invokes creativity turn leads sustainable corporate purchased electric power growth accordingly actively promote diversity including natural gas active participation female employees heavy oil etc otsuka pharmaceutical purchased steam coal etc otsuka pharmaceutical factory renewable energy taiho pharmaceutical scope calculated consolidated subsidiaries otsuka group compa otsuka chemical number female managers female manager ratio nies constitute top co emissions originating energy otsuka warehouse scope companies otsuka pharmaceutical otsuka pharmaceutical factory taiho pharma otsuka foods ceutical otsuka chemical otsuka warehouse otsuka foods number employees acquiring childcare leave ghg emissions throughout value chain fiscal number number employees acquiring childcare leave ghg emissions emissions scope categories thousand tonsco otsuka group supports employees achieving balance scope otsuka group assesses environmental impacts throughout category b oe pt ew ne ine gn oc fh til hd rc ea er e w rd kp w lao cr ek n uh rr eu ryg fh cm ile ita ies su r te hs e n hc olu ldd ii nn gg oth f e e pm f r ooi ds us urio c tn ss l df rom use eh ne v iv roa nlu ec nh ta ai ln mfo pr ait cs sf v ine ada djo itr io c top ea mni ie ss ioin n j sa dp ua en tw ch rl par og te seminars achieving balance childcare work thousand tonsco scope activities scopes calculate emissions stemming enhancement various related systems activities suppliers customers parties scope continue efforts calculate greenhouse category emissions purchased gas ghg emissions aim reducing co goods services number emissions throughout value chain female male female scope companies otsuka pharmaceutical otsuka pharmaceutical factory taiho pharma companies otsuka pharmaceutical otsuka pharmaceutical factory taiho pharmaceutical male ceutical otsuka chemical otsuka warehouse otsuka foods otsuka chemical otsuka foods otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report nonfinancial highlights water usage water use efficiency thousand thousand million water usage business target improve water use efficiency thousand compared strategy assess state water risk amount water used section manufacturing sites around world work achieve communitybased management effective use water resources order achieve sustainable society r esearch development outside japan japan rd activities scope calculated consolidated subsidiaries otsuka group compa pharmaceutical business nies constitute top co emissions originating energy c ore product development p rojects phase ii later resource recycling rate final disposal amount stages pharmaceutical business tons resource recycling rate social challengesstrengths overview verview therapeutic otsuka group companies japan promoting areas recycling reuse resources achieved recy aking challenge cling rate zero emissions based internal standard addressing unmet medical recycling rate higher fiscal needs continue striving zero emissions undertaking nutraceutical business rs reduce reuse recycle social challengesstrengths final disposal amount resource recycling rate overview scope major consolidated subsidiaries japan global expansion rd framework c onsumer products business businesses th research center tokushima research institute pictured otsuka groups drug discovery center building houses pharmacology synthesis departments also provides space researchers different disciplines freely exchange information engage discussion otsuka holdings co ltd integrated report business strategy section research development rd activitiespharmaceutical business powered aggressive rd investments aim contribute unmet medical needs creating inno proprietary drug discovery business model pharmav aa cen uir ticals visterra inc vative products generating new strengths innovation group cooperation rd policy pharo mt asu cek ua tical factory astex pharmaceuticals driven corporate philosophy otsukapeople creating n toe w ac hp ir eo vd eu hct igs hfo lyr ib ne nt ote var th ive ea l dth ru w g dr il sd cw ovid ee ry oth fe ss ou lk ua iog nro su fp ra ims rd expenses inhouse drug discovery pharo mt asu cek ua tical pharmta ai ch eo utical unmet medical needs goal mind engage multi billion lateral rd activities addition collaboration group companies boast ing expertise numerous fields working bolster otsuka group built solid foundation continues inhouse drug discovery platform including human resources devel drive innovation ahead time drug opment access innovative technologies ideas discovery research centering otsuka pharmaceutical involving research support networkbuilding universities rd strengths areas psychiatry neurology rd expenses latephase development research institutes bioventures possess leadingedge ratio projects taiho pharmaceutical possesses drug discovery research technology drug discovery seeds technology platform focus oncology otsuka ratio inhouse drug discovery projects latephase development projects pharmaceutical factory leading company intravenous rd expenses pharmaceutical business solutions also welcomed group astex phar phase ii later stage development december maceuticals pioneer fragmentbased drug discovery avanir pharmaceuticals boasts strengths develop ment field neurological diseases visterra inc rd bases company possessing unique antibody platform technology china tsuka pharmaceutical development mutually sharing cuttingedge proprietary technology inherent tsuka shanghai research institute commercialization inc basic research tsuka beijing research institute astex pharmaceuticals viewpoints strong desire challenge difficulttotreat clinical development aiho pharmaceutical beijing co ltd clinical development diseases continuing take rd next level vanir pharmaceuticals inc south korea aiho oncology inc generate new strengths innovation k orea otsuka pharmaceutical co ltd visterra inc singapore aiho pharma singapore pte ltd topic europe hierotope platform visterras proprietary antibody platform technology japan us visterra possesses proprietary antibody platform technology hierotope platform enables design antibody drugs asia tokushima otsuka pharmaceutical targeting identified epitopes thought essential pro epartment drug discovery strategy tein function simulating computer binding epi epartment medical innovations shiga epartment cns research topes substructure countless antibodies hierotope epartment renal cardiovascular otsuka pharmaceutical research fujii memorial research institute refers region comprised robust threedimensional edicinal chemistry research laboratories hyogo structure amino acids believed play critical role epartment lead discovery research otsuka pharmaceutical okushima research institute ako research institute structure function activity protein using combina uk astex pharmaceuticals f iarm gnu ola st ti io c n r ive iss ie oa nr c rh ds dit eu pte artment ibaraki tion computational experimental methods technol drug discovery preclinical taiho pharmaceutical taiho pharmaceutical ogy designs engineers antibodies strongly bind development discovery preclinical research division tsukuba area tsuka europe development ti os kco uv sher imy ad p ar eclinical research division tokyo hierotope unlike traditional approaches completely novel commercialization ltd taiho pharma europe ltd otsuka pharmaceutical factory otsuka pharmaceutical technology enables design development antibodies n aruto research institute research diagnostic division rd department disease drug discovery targets hitherto considered diffi germany development center headquarters clinical development otsuka novel products gmbh technical center otsuka pharmaceutical factory cult thus aim provide new therapeutic drugs diseases research development center clinical development unmet medical needs still remain department taiho pharmaceutical clinical development division osaka otsuka pharmaceutical headquarters clinical development otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report business strategy section research development core product development tas trial ongoing drug candidate treating gastroin psychiatry neurology tas potential exhibit antitumor effects inhibit testinal stromal tumor gist one rarer forms cancer ing heat shock protein hsp destabilizing reducing japan gist malignant type tumor occurs wall brexpiprazole track designation us food drug administration fda multiple proteins involved cancer growth survival hsp gastrointestinal tract many patients often experience brexpiprazole new antipsychotic agent novel mecha clinical trials avp also ongoing psychiatric known particularly important survival mainte recurrence metastasis incidence rate japan around nism action known serotonindopamine activity modulator neurological disorders many unmet medical needs nance cancer cells expressed highly cancer cells per people sdam sold brand name rexulti adjunc exist patients negative symptoms schizophrenia tumor tissue exists highly activated state phase iii tive therapy major depressive disorders schizophre traumatic brain injury intermittent explosive disorder cardiovascular renal nia treatment us japan europe used centanafadine schizophrenia treatment clinical trials currently underway centanafadine triple reuptake inhibitor action mechanism utilize properties agent order provide effective modulates norepinephrine serotonin dopamine vadadustat ultrasound renal denervation treatment device methods treatment unmet fields agitation reuptake currently undergoing phase iii trials us vadadustat oral therapeutic drug currently subject phase renal denervation system new treatment method associated dementia alzheimers type posttrau candidate attention deficit hyperactivity disorder adhd iii trials candidate treatment anemia associated potential effectively lower blood pressure patients matic stress disorder ptsd adults adhd developmental disorder characterized diffi chronic kidney disease nondialysis dialysis patients hypertension existing hypotensive drugs unable estimated approximately million people culty paying attention easily distracted forgetful excessive works stabilize modulate hypoxiainducible factor technology downregulates hyperactivity renal g countries suffer alzheimers many patients activity impulsiveness fidgeting unable sit still hif transcription factor activates erythropoietin sympathetic nerves using catheterbased system percuta said exhibit form behavioral disorder estimated us million potential adhd inhibiting hif prolyl hydroxylase hifph enzyme breaks neously deliver ablations sympathetic nerves surrounding excessive motor activity verbal aggression physical aggression patients among adults million among children hif hif responds changes oxygen concentration renal arteries heat generated radio ultrasound symptoms impact patientthey fundamental treatment method stimulant drugs usually controls gene expression involved production red blood waves renal denervation device developed place strain family members caregivers significantly prescribed pose problems effect cells hif also acts improve iron mobilization coordinat usbased otsuka group company recor medical utilizes mini affect quality life ptsd mental disorder develops central nervous system mental dependency drug resis ing interdependent processes boosts red blood cell production mally invasive procedure blood vessel walls efficiently result exposure traumatic event experiencing severe tance abuse stimulants also seen problem ultimately oxygen delivery agreement achieve nerve ablation effects system characterized mental stress including earthquakes natural disasters accordingly safer drug lower risk abuse akebia therapeutics otsuka group acquired rights delivering ablations concentrically renal sympathetic nerves fires accidents violence criminal damage person suffering achieve comparable efficacy stimulant drugs needed joint development marketing vadadustat us joint using ultrasound energy artery wall kept cool ptsd may afflicted traumadriven fear anxiety development exclusive marketing europe exclusive circulating water within artery trials currently underway attentiondeficithyperactivity disorder epidemiology mature markets data even long time elapsed number ptsd patients total pediatric adult adhd prevalent cases dsmiv full detail drdecision development marketing canada australia china us investigate treatment hypertension resources llc rights reserved reproduction distribution transmission publica g countries estimated around million tion prohibited countries excluding central south america japan south korea examine potential treating fremanezumab refractory hypertension provides combination partial agonist activity serotonin hta dopamine countries outside japan asia taiwan south korea singapore malaysia indonesia receptors antagonist activity serotonin hta receptors fremanezumab anticalcitonin generelated peptide cgrp etc mitsubishi tanabe pharma acquired license drug alzheimers disease epidemiology mature markets data total prevalent cases ad drdecision resources llc rights reserved reproduction distribution monoclonal antibody prevention migraines admin transmission publication prohibited istered monthly subcutaneous injection expected post traumatic stress disorder epidemiology mature markets data total expected completion phase iii trials key drug developments end june month prevalent cases full detail dr decision resources llc rights reserved prevent migraines selectively binding cgrp thought reproduction distribution transmission publication prohibited key factor cause migraines thus inhibiting cgrp psychiatry neurology avp binding receptor otsuka group concluded avp new compound deuteriummodified dextro exclusive license agreement teva pharmaceutical industries fremanezumab fremanezumab centanafadine avp episodic migraines chronic migraines adhd adults agitation alzheimers dementia methorphan quinidine drug currently studied development commercialization japan drug piiiiijapan sep piiiiijapan oct piiius may piiiuseurope jun phase iii trials candidate moderatetosevere agitation currently undergoing phase iii trials japan candidate avp brexpiprazole patients alzheimers dementia granted fast prevention episodic chronic migraines agitation alzheimers dementia agitation alzheimers dementia piiiuseurope oct piiiuseurope dec oncology cancer supportive care guadecitabine astx guadecitabine nextgeneration lowmolecularweight dna astx worlds first oral dna methylation inhibitor com methylation inhibitor designed allow active metab bination drug containing dna methylation inhibitor decit vadadustat vadadustat olite decitabine work longer body thereby effi abine metabolic enzyme cytidine deaminase inhibitor guadecitabine renal anemia dialysis renal anemia nondialysis relapsedrefractory aml piiiuseurope mar piiiuseurope aug ciently reach tissues bone marrow currently cedazuridine administration currently approved methyla piiiglobal sep phase iii trials two indications relapsedrefractory acute tion inhibitors requires patients visit hospital intrave tolvaptan opc guadecitabine siadh cardiac edema myeloid leukemia aml adults relapsedrefractory myelo nous injection orally administered astx relapsedrefractory mds piiijapan mar piiijapan jul piiiglobal jun dysplastic syndromes mds adults potential become new treatment option alleviates cardiovascular renal burden mds patients met primary endpoints phase iii trials treatment mds aiming submit oncology cancer supportive care application approval end otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report business strategy section research development projects phase ii later stages march psychiatry neurology cardiovascular renal code generic name brand name country development status code generic name brand name country development status origin indication origin indication features region phase ii phase iii filed approved features region phase ii phase iii filed approved major depressive disorder jp eu cn opc tolvaptan otsuka syndrome inappropriate antidiuretic hormone samsca jp agitation associated dementia pharmaceutical secretion opc brexpiprazole otsuka alzheimers type jp us eu v receptor antagonist rexulti pharmaceutical dopamine partial agonist bipolar disorder us eu opc otsuka cardiac edema jp posttraumatic stress disorder us eu v receptor antagonist pharmaceutical ep roc ni n n repinephrine dopamine reuptake inhibitor phts au rmka ceutical attention deficit hyperactivity disorder us hik fb pr ly l h yd rv oxa yd laa sed u ins ht iba r akebia anemia associated chronic kidney disease us eu tas taiho duchenne muscular dystrophy jp pgd synthase inhibitor pharmaceutical agitation associated dementia us eu areas alzheimers type avp nd du ate rr ei cu em ptom r ao nd tai gfi oe nd td se ex rotr nm ine nh nr op rh epa n e pq hu rii nn ei dine avanir negative symptoms schizophrenia us c feo atd ue sgeneric name brand name origin indication c ro eu gn iotr ny phase ii pe hv ae sl eo p iim ent f lt ea dtus approved reuptake inhibitorsigma receptor agonist traumatic brain injury us opc delamanid intermittent explosive disorder us deltyba otsuka multidrugresistant tuberculosis us pharmaceutical eb centanafadine mycolic acid biosynthesis inhibitor neurovance attention deficit hyperactivity disorder us norepinephrine dopamine serotonin reuptake inhibitor opc otsuka tuberculosis us lu aa nalmefene dpre inhibitor pharmaceutical selincro lundbeck alcohol dependence jp opioid receptor antagonist opa otsuka atopic dermatitis jp tev fremanezumab pde inhibitor pharmaceutical teva migraine jp anticgrp antibody ops otsuka clostridium difficile infection enteric infection jp new quinolone based antibacterial agent pharmaceutical oncology tas taiho stress urinary incontinence jp selective norepinephrine reuptake inhibitors pharmaceutical code generic name brand name country development status origin indication tas taiho features region phase ii phase iii filed approved multikinase inhibitor pharmaceutical idiopathic pulmonary fibrosis jp colorectal cancer cn tas trifluridine tipiracil taiho tas taiho rheumatoid arthritis jp lonsurf us btk inhibitor pharmaceutical pharmaceutical interference function dna gastric cancer jp eu otsuka opf pharmaceutical peripheral parenteral nutrition solution jp tas tegafur gimeracil oteracil folinate taiho gastric cancer jp glucose electrolyte amino acid fat vitamin factory antimetabolite pharmaceutical tas taiho nonsmall cell lung cancer jp us eu vis visterra influenza infection us dutpase inhibitor pharmaceutical antihemagglutinin monoclonal antibody tas taiho multikinase inhibitor pharmaceutical prostate cancer jp tac meiji detrusor underactivity overactive bladder jp tas taiho gastrointestinal stromal tumor jp hsp inhibitor pharmaceutical tas taiho diagnostics cholangiocarcinoma jp us eu fgfr inhibitor pharmaceutical tas taiho code generic name brand name country development status urothelial cancer jp origin indication peptide vaccine pharmaceutical features region phase ii phase iii filed approved taiho tas solid tumors us eu ccac otsuka pharmaceutical measurement gastric acidity jp ccalcium carbonate breath test pharmaceutical ovarian cancer us eu sgi guadecitabine odkcn otsuka astex acute myeloid leukemia jp us eu diagnosis myelodysplastic syndrome cn dna methyltransferase inhibitor wt mrna rtpcr assay kit pharmaceutical myelodysplastic syndrome jp us eu phase iiiii astx astex myelodysplastic syndrome us phase iii dna methyltransferase inhibitor application takara bio inc astx astex solid tumors lymphomas us iap inhibitor tbi takara bio synovial sarcoma jp nyeso sitcr gene therapies tbi canerpaturev takara bio melanom jp oncolytic virus tbi takara bio acute lymphoblastic leukemia jp cd car gene therapies pronetu fosnetupitant helsinn chemotherapyinduced nausea vomiting jp nk receptor antagonist healthcare otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report business strategy section pharmaceutical business social challengesstrengthsoverview providing total healthcare solutions disease diagnosis treatment fiscal business overview mainstay products fiscal revenue profit boosted higher sales revenue new products japan overseas despite impact drug price revisions japan lower sales revenue longlisted drugs owing campaigns promoting use generics higher rd costs associated progress made latephase development products sales revenue came billion revenue ratio business performance fiscal yoy operating profit billion billion japan revenue operating profit abilify maintena rexulti north america others revenues external customers antipsychotic longacting injectable antipsychotic generic name aripiprazole origin otsuka pharmaceutical generic name brexpiprazole origin otsuka pharmaceutical abilify maintena oncemonthly longacting injectable global alliance lundbeck novel atypical anti antipsychotic agent abilify discovered otsuka pharmaceutical psychotic agent rexulti approved us commercialized global alliance lundbeck drug adjunctive therapy major depressive disorder therapeutic treats schizophrenia adult patients first launched us drug schizophrenia japan europe approved social challenges otsukas strengths europe japan currently sold therapeutic drug schizophrenia countries sales revenue fiscal increased year drugs high efficacy safety based novel mecha year billion mainly reflecting greater awareness nism action rated favorably physicians patients line evolution life sciences number new corporate culture efficacy indication convenient formulation well alike helped boost fiscal sales revenue year drugs discovered every year however still many generates innovation increase prescriptions following july addition mainte year billion diseases lack effective treatment methods diseases every otsuka group employee high regard nance treatment bipolar disorder adults approved indica existing treatment drugs unsatisfactory address tion us jissho actualization sozosei creativitythe dna ing desire people remain healthy universal corporate cultureand pursues innovation daily basis pressing issue always questioning common practice rd departments pharmaceutical business consistently samscajinarcjynarque onsite operations embraced challenge solving issues standpoints patients medical professionals alike roughly years mainly fields psychiatry neurology well oncol providing total healthcare ogy many unmet needs still exist solutions diagnosis treatment disease employ holistic approach peoples health conduct business wide array fields including pharmaceuticals clinical nutrition diagnostic agents medical devices order vreceptor antagonist provide comprehensive healthcare solutions diagnosis generic name tolvaptan origin otsuka pharmaceutical approved use countries treatment disease prescriptions drug oral aquaretic continued samscajinarcjynarque sold globally since increase fiscal mainly reflecting strong recommendations oral aquaretic drug brand name samsca novel mechanism various guidelines japan treatment hepatic edema longheld knowledge core action excretes water body direct impact cardiac edema prescriptions treatment adpkd also continue therapeutic areas electrolyte excretion inhibiting antidiuretic hormone vaso grow back approved sales markets europe sales pressin approved worlds first therapeutic drug also commenced us may sales revenue rose since commencing rd fields psychiatry neurology autosomal dominant polycystic kidney disease adpkd year year billion samsca grew sharp oncology continue take steps address brand name samscajinarcjynarque year year billion jinarcjynarque unmet medical needs spawn innovation various forms otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report business strategy section pharmaceutical business overview therapeutic areas psychiatry neurology oncology cancer supportive care fields psychiatry neurology key areas focus otsuka given many diseases causes expanding business fields oncology cancer supportive care aim providing yet discovered difficulties involved drug discovery rd continue embrace patientoriented total care collaboration group companies access cuttingedge challenge providing trailblazing solutions aim rehabilitate patients back society suffering knowledge innovative technology seek achieve even higher level drug discovery psychiatric neurological disorders aiming provide systematic solutions address challenges psychiatric sparking new innovation melding proprietary technologies neurological healthcare launch tegafurbased oral formulation futraful numerous compounds owing proprietary fragmentbased japan taiho pharmaceutical pioneered market drug discovery addition dna methylation inhibitors psychiatric disorders schizophrenia bipolar major prescribed patients countries regions oral anticancer agents time use still guadecitabine astx successor drugs developed depressive disorder cause problems persons social life career worldwide harnessing rd experience abilify draw uncommon half century anticancer drug research since leveraging knowledge dacogen generic name decitabine studies develop time childhood ing feedback professionals engaged clinical practice company generated large body evidence treatment myelodysplastic syndromes acute myeloid late middle age moreover concerns growing developed rexulti new drug completely novel mecha contributed establishment cancer chemotherapy leukemia company currently promising drugs increase alzheimers populations worldwide continue nism action rexulti advancing research japan primarily ts combination drug tegafur gimeracil undergoing clinical trials age diseases affect patients quality life address yet unmet major therapeutic needs left untreated world place strain family caregivers create burden widefor example schizophrenia major depressive disorder ptsd oteracil potassium become standard treat cancer therapy systems currently changing rapidly healthcare economy still many illnesses satis agitation associated alzheimers disease ment unresectable advanced recurrent gastric cancer result advancements science technology devel factory treatments yet established causes developing bringing market longacting inject standard postoperative adjuvant chemotherapy gastric oping expanding drug discovery platform technology mechanisms fully understood makes dis ables like abilify maintena address issue medication cancer development commercialization harnessing respective strengths group company covery new drugs extremely difficult adherence trialing use abilify mycite worlds first anticancer agent lonsurf subsequent establish also stepping pace research development ment sales framework north america development collaborations alliances tieups corporations otsuka group started conducting research develop digital medicine system patients record tablet inges sales alliance francebased servier taiho pharmaceutical academia including open innovation initiatives seek ment fields psychiatry neurology tion developing digital therapeutic applications treating continues take challenge expanding global pres promote access cuttingedge knowledge innovative tech day continue work tirelessly new drug development major depressive disorder continue focus unmet ence value creation nology achieve even higher level drug discovery goal contributing medical needs disciplines needs patients aim providing systematic solutions results research quarter century came address challenges psychiatric neurological healthcare astex pharmaceuticals became part otsuka core product development p head development abilify worlds first dopamine unique approach fusing together different technologies group contributing commercialization partial agonist evaluated highly clinical settings effi core product development p cacy safety based novel pharmacological action unmet medical needs psychiatry neurology unmet needs oncology schizophrenia gastric cancer schizophrenia psychiatric disorder thoughts emo gastric cancer fifth common type cancer world tions continue disordered appearing adolescence third common cause cancer death following age maturity presents symptoms hallucina lung colorectal cancer estimated approximately tions delusions thought disorders emotional flattening lack people die gastric cancer every year japan motivation make employment living society difficult common form cancer responsible roughly even today advance science causes disease deaths annually surpassed lung colon cancer fully elucidated need longterm remarkable progress made recent years success therapy support aimed return society ameliorating fully treating gastric cancer survival period dramatically symptoms another issue lack recognition disease increased past years said intensive chemotherapy reduced medication adherence due side effects lead used treatment cancer progresses relapse patients many complications arise drugs used estimated million patients us also limited extending survival period alleviating symp misunderstandings prejudices regarding psychiatric neurological collaboration shizuoka cancer center taiho pharmaceutical million japan million five major countries disorders still exist society fully understood otsuka toms latestage treatment metastatic gastric cancer provides information help improve lives cancer patients europe pharmaceutical confronting issues head carrying numer challenges new treatment options certainly needed offers support people experienced cancer overcome ous activities aimed educating people diseases challenges face daily life together family healthcare schizophrenia epidemiology mature markets data drdecision resources llc httpswwwotsukacojpenknowproject ferlay j soerjomataram dikshit r et al int j cancer e professionals cancer survivors rights reserved reproduction distribution transmission publication prohibited latest cancer statistics cancer information service national cancer center reprinted permission japan japanese otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report business strategy section pharmaceutical business adpkd treatment samscajinarcjynarque taking challenge addressing unmet medical needs cardiovascular renal guided motto otsuka otsuka group continued develop pharmaceuticals novel mechanisms action efficacy various diseases samscajinarc jynarque offers lot hope new drug renal field treatment autosomal domi one core therapeutic area addition psychiatry neurology oncology nant polycystic kidney disease adpkd condition hitherto known treatment since first inhouse developed pharmaceutical hypotensive aggressive growth investments illustrated vadadustat adpkd characteristics number patients countries result drug approved japan drug mikelan launched continued contribute business alliance akebia therapeutics acquisition autosomal dominant polycystic kidney disease adpkd europe us additional clinical trials treatment cardiovascular diseases thanks ground visterra company product pipeline renal domain rare hereditary disorder many fluidfilled sacs cysts requested fda eventually approved breaking novel drug discovery notably antiplatelet agent also strive find solutions unmet needs nonphar form kidneys gradually grow larger thereby made available anxiously waiting patients pletaal worlds first oral aquaretic drug samsca maceutical areas propelling development causing symptoms pain swollen abdomen country development groundbreaking drug also establishing new assets overseas example unique medical devices fuse innovative technology eventually leading decline renal function around half rated highly patients medical professionals alike efforts develop worlds first therapeutic drug adpkd strengths drugs clinical research examples initiative adpkd patients develop endstage renal failure age may otsuka selected receive corporate seeking make sustained contributions unmet needs include ultrasound renal denervation treatment device require dialysis kidney transplant incidence innovator award us national kidney foundation rate adpkd around one person every taking aquaretic drug turning treatment patients cardiovascular renal fields intend peripheral artery stent people estimated roughly patients adpkd unprecedented challenge extremely strengthen inhouse drug development also make core product development p japan us long road take single therapeutic drug incurable disease extremely encouraging devel samscajinarcjynarque opment patients physicians samscajinarc development approval jynarque truly product embodies motto research drug started physician said want otsuka areas diuretic excretes water conventional diuretics used treat edema drawback causing excretion samscajinarcjynarque water also electrolytes needed otsuka groups future providing total healthcare human body troubling issue physicians whereas previously patients option controlling hampered treatment illnesses associated symptoms adpkd like high blood pressure started research focus vasopressin high expectations firstever treatment countries clinical nutrition intravenous solutions diagnostic agents six years later discovered lead com product sold ahead intend promote fiscal sales revenue fiscal sales revenue pound led development aquaretic drug proper use among patients proceed next stage today meanwhile actually saving lives mainly monitoring effects years research first commenced drug shown treatment longer periods moreover otsuka group billion billion effective adpkd mice following clinical trials concluded comprehensive partnership agreement finally approved roughly year journey japan kidney association purpose raising awareness years experience clinical nutrition companion diagnostics play key role identifying individ worlds first therapeutic drug adpkd adpkd improving level medical care business otsuka group continues contribute large ual differences effects drugs side effects reason drug took long time partnership aim assistance patients number patients leading company japan area appropriate healthcare provided otsuka group approved existing drugs treating families leveraging respective strengths intravenous solutions made first foray overseas provides diagnostic agents meet international standards adpkd therefore fullscale clinical studies ever accumulated experience party guided motto markets clinical nutrition business opera including products support companion diagnostics wide conducted disease meant primary clinical otsuka continue indicators established condition cleared embrace new challenges future tions spread across companies worldwide busi range fields digestive organs respiratory organs clinical trials conducted patients ness continues grow centering basic solution business infectious diseases cancer cardiovascular system going forward continue develop high valueadded companion diagnostics diagnostic tests used identify patients likely products meet market needs around world contribute benefit particular therapeutic agent determine optimal dose otsuka global healthcare path firstinclass treatment adpkd applaud efforts clinical development team otsuka perseverance diligence developing tolvaptan patients adpkd launch jynarque otsuka groups market share us means tolvaptan available patients adpkd japan eu north america several countries launch finally brings journey intravenous solutions completion researchers started program addition japan testament many patients healthcare providers participated clinical trials adpkd without dream could never become reality hope launch jynarque brings new options patients adpkd finally want congratulate commercial team us success launch louis allesandrine vice president nephrology jynarque wish continued success bringing jynarque adpkd patients mdd sales marketing otsuka america pharmaceutical inc receiving award copyright iqvia robert mcquade kevin longino pictured right chief executive calculated based jpm dec mat executive vice president chief strategic officer officer us national kidney foundation reprinted permission otsuka pharmaceutical development commercialization otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report business strategy section nutraceutical business nc business social challengesstrengthsoverview supporting management improvement everyday health product categories innovative products based scientific evidence functional beverages functional foods revenue ratio business performance fiscal billion fiscal sales revenue billion fiscal sales revenue billion japan revenue operating profit functional beverages category mainly develop functional foods sell nutrition products health north america innovative products based scientific evidence mainstay foods mainstay products include calorie mate balanced others products include pocari sweat developed nutritional food containing five major nutrients gave based rehydration drink concept thus paving birth new genre nourishment soyjoy soy bar way new ionsupply drinks market tiovita drink made whole soy beans gives energy drink containing taurine vitamins carnitine nutrition soy beans lineup organic glu chloride oronamin c drink carbonated energy drink tenfree products sold countries containing multiple vitamins highfiber drink europebased nutrition sant fibemini food specified health uses foshu regulate gastrointestinal condition revenue sales external customers social challenges otsukas strengths healthy desire people worldwide even though innovative products based advancements medical technology improvements scientific evidence nutritional others public health helped boost global average life expectan draw knowhow accumulated pharmaceutical supplements including new products cies aging populations increase lifestyle diseases business develop innovative products based scientific chronicphase medical care pushed healthcare costs evidence threaten sustainability social security schemes given seriousness issue importance managing fiscal sales revenue billion fiscal sales revenue billion health awareness based improving ones daytoday health accordance cultural product category main brands nature also developed many unique products lifestyle habits well life stage expected become product value made nutritional supplements free flavorings colorings equelle contains equol support womens increasingly important years ahead nutraceutical create innovative new markets persistently carrying preservatives passed rigorous qualitystan health beauty kenjanoshokutaku double support business hereinafter referred nc business helps product value awareness activities campaigns health fields dard process procurement raw materials right food specified health use slows bodys people world longevity healthy independent lives related products continue offer new value part quality testing megafood supplements absorption sugar lipids thereby reducing rise providing innovative products aim maintain improve nering inhouse research institutes external organi derived natural food sources fruits vege blood glucose levels triglycerides meal otc health along beneficial information human health zations conduct research even product launch tables innate supplements marketed medical products like oronine h ointment treating skin ail institutions ments cuts cosmedics concept skincare global network brands innersignal ulos portmanteau cosmetics medicine contribute health people worldwide mutually exploiting global network product attributes strengths infrastructure group company share information global health issues product categories changed fiscal please see earnings results material details otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report business strategy section nutraceutical business global expansion guided philosophy contributing health people worldwide engage business activities accordance culture health issues region japan north america average life expectancy japan men women among associations also developing new products provide us selfmedication prevalent selfmedication product categories highest world new challenge society solutions next challenges undertake initiatives broaden demand continues increase mainly skyrocketing medi daiya foods develops manufactures sells highquality emerging gap life expectancy healthy life interaction society depending circumstances cal costs recent years innovative plantbased food products cheese alternatives expectancy words period persons pharmavite leading company us supplement industry yogurt alternatives dressings desserts companys product daily life hindered health problems otsuka group produces supplements based safety efficacy consulting range enjoyed vegetarians people food aller drawn extensive knowhow accumulated pharmaceutical experts develop products incorporate stateoftheart gies also healthconscious millennials business develop innovative products based scientific evidence science companys high quality supplements meet strict us news world reportpharmacy times survey product categories letter recent years continued conduct research quality criteria set united states pharmacopeia usp vitamins ae coenzyme q omegafish oil flax seed oil herbal supplements mood health supplements diabetic multivitamins garlic supplements cholesterol key topic extending healthy life expectancy furthermore carrying leading brand recommended pharmacists across nine management fish oil rd utilize accumulated insights coordinate activi ties promote public awareness importance hydration replenishment electrolytes prevention heatstroke activi ties teach people importance eating wellbalanced meals initiatives support womens health goal promoting health productivity management empower ment women aim solve health issues commu nities teaming local governments schools corporations providing information support womens health asia addition risks heatstroke tropical diseases infectious established new halalcertified manufacturing lines oronamin c diseases tropical regions demand rising asia hydration drink soyjoy plant commenced production nutrition result people playing sport greater sales products indonesia awareness health issues source euromonitor international retail value rsp launching pocari sweat hong kong taiwan europe expanded reach setting production sites pocari sweat overseas sales volume cases china south korea taiwan indonesia end pocari sweat available countries region organic food market europe grown recent years manufacturer bc bio group catering expanding worldwide healthconscious consumers demand safer trust consumer needs strengthening freefrom product range indonesia first launched market share worthy food accordingly socalled freefrom foods alternative source euromonitor international retail value rsp sports drink category increased owing products attracting attention millennialsin fiscal communitybased promotion activities efforts educate meatfree food market worth approximately billion share sales indonesia consumers importance hydration electrolyte replen grown rapidly past five years cagr sports drink category ishment order comply indonesias cultural norms glutenfree food market worth around billion expanding cagr headquartered south france nutrition sant derives name french words nutrition health company manages portfolio mostly health food brands sells products countries around world focus european markets plants company obtained ifs international food pro duction standard guarantee high level product quality management constructed new plant france production glutenfree food welcomed organic food otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report business strategy section nutraceutical business consumer products business rd framework product development based scientific evidence nc business research institutes conduct research topics nutrition exercise unique view consumer products business delivers points utilize knowhow honed pharmaceutical business develop provide world familiar foods beverages deli innovative products based scientific evidence maintain improve peoples health cious safe reassuring healthy saga nutraceuticals research institute otsu nutraceuticals research institute since establishment japans first private research insti otsu nutraceuticals research institute established tute clinical exercise nutrition facility conducted rd order research topic gut immunity partic activities various subject fields address exercise nutrition ular focus intestines play key role life support womens health health issues one largest research conducted topic enhancing bodys bio sales revenue business performance fiscal fiscal business overview artificial environment control rooms japan built insti logical barrier increasing secretion immunoglobulin iga ratio billion tute enabling recreation high temperaturehigh humidity antibody plays crucial role mucosal immunity human sales revenue consolidated fiscal year came low temperaturelow humidity environments may found clinical trials demonstrated lactic acid bacteria b heightens sales revenue operating profit billion yoy decrease mainly reflects hypoxic environments maximum altitude meters function mucosal immunity lowers probability impact lower domestic sales volume crystal conditions thus far proved difficult replicate catching common cold geyser mineral water products despite new chamber help research sports nutrition yearonyear sales volume increase carbonated effects fluid nutritional intake harsh environments vitamin drink match owing higher otc sales aggressive marketing strategy improved recipe mixed berries flavor berry match operating profit decreased billion yoy owing partly decline equitymethod gains revenue sales external customers topic topic worlds first retort curry born sterilization technology knowhow intravenous solutions business using science support women 's vital energetic lives otsuka foods launched sales bon curry worlds effective bon curry gradually became staple japanese institute discovered close relationship wom first commercially available curry retort pouch drawing dinner tables ans health equol isoflavandiol estrogen metabolized inspiration vacuumpacked readytoeat sausages used bon curry celebrated th anniversary shigeto uchiyama soy bean isoflavones bacterial flora intestines insti military applied sterilization techniques date total three billion packs product sold fellow saga nutraceuticals tute successfully isolated lactococcus strain lactic acid knowhow groups intravenous solutions business based concept reliability safety product research institute bacterium produces equol using lactic acid bacteria nutraceutical business division successfully develop process trial error still free preservatives artificial colorings otsuka pharmaceutical co ltd produce equol fermenting soy germ finally created reliable safe food product easily consumed vegetable ingredients series japangrown since equolcontaining supplement equelle years home developing product insisted must bon curry products sold japan heated rd collaboration pharmaceutical divisions us contain preservatives stored long periods microwave oven without need remove cardboard light issues expanding healthy life expectancy affiliates launched equelle gele support room temperature following products launch uncon packaging thus making preparation reliable safe advancement womens empowerment understanding fundamentals womens beauty health ventional marketing campaign using enamel signs proved meal todays busy families even faster field womens health growing increasingly important otsuka pharmaceutical continues excluding ganso bon curry limited sale okinawa otsuka pharmaceutical started lending assistance investigate various possible health global joint research studies cardiovascular diseases benefits equol nutrition initiated others since explored hope offer support wom numerous possibilities soy beans many years ens health providing information example taking part projects elucidate relationship developing products address diet longevity study focused isoflavones con various issues stage womans tained soy beans conducted saga nutraceuticals research life otsuka pharmaceutical conducts broad range studies maintaining health women menopausal symptoms bones skin health blood vessels following website provides information various studies httpswwwotsukacojpenhealthandillnesslivingwellwithmenopauseequolresearch vintage enamel sign removal sprouts potatoes performed totally hand original retort pressure cookerspressure heat sterilization high temperature enables long shelf life without use preservatives otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report businesses expanding businesses multilater ally focus chemical products foundation warehousing transportation value sales revenue business performance fiscal fiscal business overview creation ratio billion revenue functional chemical products increased year sales revenue operating profit year mainly owing sales volume growth products hydrazine hydrate friction materials revenue fine chemicals declined year year due chiefly otsuka group csr impact orders pushed back transportation warehousing revenue grew year year thanks society increase volume group products handled well expansion shared platform joint distribution environment external customers result sales revenue consolidated fiscal year came governance billion yoy operating profit billion irectors audit revenue sales external customers supervisory board members topic otsuka warehouse accelerates workstyle reform initiative completion cross dock harumi building october otsuka warehouse completed full renova contributes otsuka warehouses efforts develop human tion yearold distribution facility harumi building resources promote workstyle reforms tokyos chuo ward transforming new leased office logistics crossdock facility one unloads different cargo multiple space origins resorts item ready shipped different destinations suggested name cross dock logistics industry term offices otsuka warehouse designed idea employees share information opinions broaden reach space interact different people within outside company departments work floor walls removed floor also kitchen caf human resource development space employees openly communicate institute employee presentations given every day atop institute pictured established stage time time speakers outside com aim nurturing human resources unshack pany also deliver lectures spot new office led conventional ideas successful fore functions space enhance intellectual experiences otsuka group contin productivity exchange knowledge generates also uously generate innovation change building features monuments symbolic metaphorical paradigm shift includ ing giant tomato tree bent giant cedar floating stones otsuka holdings co ltd integrated report foundation value creation otsuka group csr toward realizing sustainable society otsuka group recognizes csr integrated businesses proactively promotes csr based otsuka groups materiality related sdgs corporate philosophy materiality social issues goals activities related sdgs society health unmet medical contribution unmet needs promotion rd unmet needs health needs solution rd antituberculosis drugs spread inflec eradication tuberculosis improvement drug access tions diseases creation system support peoples health maintenance nutritional needs realization healthful life improvement mainly exercise increasing aging healthy life extension nutrition etc enlightenment activities issues promotion problem solving strength ening partnerships corporate philosophy people presentyism creation corporate culture human resource development unpaired stimulates creativity diversity promotion diversification enhance employee engagement health management quality consumption gaining stakeholder trust sustainable procurement product production pursuing sustainability design impairs levels value chain thorough quality control stable supply sustainability establishing quality assurance responsible promotional activities system safety security information provision otsukas goal deepening communication stakeholders promotion customeroriented become indispensable contributor management environ climate global warming fy goal reduction reduce co emissions throughout peoples health worldwide ment change co emissions compared value chain fy resource environmental fy goal reduction reduce environmental impact improv circula load increase simple incineration ing resource efficiency tion landfill compared fy promotion business activities aimed otsukas csr mission sustainable state society earth csr integrated businesses across otsuka group companies aims water reducing freshwa fy goal improvement understanding water resources risk conserva ter availability water use efficiency management effective use water grow contributing creation healthy sustainable society tion compared fy resources pursue objectives supported comprehensive governance system governance fragile governance longterm improvement strengthen corporate governance system corporate value thorough compliance social change risk risk identification evaluation management situation productivity go badness mind body condition despite coming work calculated using base year support united nations global compant otsuka holdings became signatory un global compact way contributing realization sustainable society business activities taking account ungcs principles also sustainable development goals sdgs healthier planet healthier society climate changeresource circulation healthpeoplequality ten principles un global compact water conservation human rights principle businesses support respect environment principle businesses support precautionary p p protection internationally proclaimed approach environmental challenges human rights principle make sure complicit principle undertake initiatives promote greater human rights abuses environmental responsibility labour principle businesses uphold freedom principle encourage development diffusion governance association effective recognition environmentally friendly technologies right collective bargaining corporate governancecompliancerisk management principle elimination forms forced anti principle businesses work corruption p compulsory labour corruption forms including extortion bribery principle effective abolition child labour principle elimination discrimination respect employment occupation otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report foundation value creation otsuka group csr society society infectious diseases one three major infectious diseases worldthe considering current situation new treatment options two aids malariatuberculosis single multidrugresistant tuberculosis urgently needed healthier society infectious disease accounting highest number entered publicprivate sector agreement fatalities years research development global drug facility gdf stop tb partnership seek resolve global health issues total healthcare perspective otsuka pharmaceutical successfully created deltyba new also pursuing drug approvals multiple countries currently antituberculosis agent currently advancing research access programs deployed government public policy away deepseated preconceptions promote development creative human resources development expanding application drug chil international institutions expanded access alliance part pursue product quality reliability viewpoint consumers dren would worldfirst well new pharmaceuti ners use deltyba promoted countries cals multidrugresistant tuberculosis furthermore health initiatives supplying pharmaceuticals even patients aim contributing improved access pharmaceuti without interruptioncontributes fair pricing country based recognition csr integrated part business operations otsuka group implements csr initiatives cals otsuka group engaged research development also creates employment even though many corporate philosophy otsukapeople creating new products better health worldwide health universal desire therapeutic drugs iv solutions address unmet needs japanese pharmaceutical companies supplying locally manufac people around world otsuka group engages activities daily basis prevent treat disease contrib also undertaking initiatives provide pharmaceuticals tured drugs risks differences technological ute maintenance improvement peoples health worldwide world live still faces host medicalrelated fair prices establish healthcare infrastructure knowhow otsuka pharmaceutical factory committed issues spread infectious diseases insufficient medical care facilities lack effective therapeutic drugs example local manufacture iv solutions local manufacture iv solutions based ambition supply aiming solve problems constantly ask accordingly carry activities defined basic pharmaceutical high clinical necessity pharmaceuticals fair prices country region find solutions unmet medical needs companies yet address whose manufacturing sales continue required person rich poor equal access healthcare moreover owing skyrocketing medical costs maintaining improving health issue society whole vision pharmaceutical industry ministry health labour welfare individuals must face headon alongside initiatives raise awareness health among individuals otsuka group also contributes initiatives maintaining improving health society large collaboration local communities partnerships global health innovative technology fund ghit fund drugs diagnostic drugs combat spread pharmaceutical business international publicprivate partnership involving japanese big three infectious diseases neglected tropical diseases government private corporations bill melinda gates mainly developing countries leveraging japans high level challenge addressing unmet medical needs foundation welcome trust united nations develop technology innovation since june otsuka pharmaceu ment program specializing funding research development tical contributed ghit fund associate partner psychiatry neurology sharp rise patients central nervous system disorders unsatisfied disorders treated patients global issue highlighted decision japans minis families eager try new therapeutic drugs nutraceutical business try health labour welfare add psychiatric disorders key focus area otsuka group making headway field big four diseases however even though many psychiatric neurological diseases namely devel psychiatric neurological diseases like schizophrenia depres opment rexulti antipsychotic drug selincro drug initiatives yettobeimagined needs sion bipolar disorder alzheimers say research decreasing amount drinking alcoholdependent development field challenging reasons patients also embracing challenge developing communitybased health maintenance promotion initiatives onset still largely unknown furthermore many therapeutic drugs diseases curative medicine far given surging costs healthcare japans aging society nutritional education prevention lifestyle diseases otsuka group promoting communitybased health mainte measures avoiding heat disorders sports promotion womens oncology nance promotion initiatives disaster prevention disaster health disaster preparedness may owing advancements medical science progress embracing challenge working gene therapy cellular relief activities example otsuka pharmaceutical carried company concluded partnership agreements prefec made year year diagnosis treatment cancer therapy new areas treatment utilizing diver various health awarenessraising educational activities tures japan still many patients effective treatment meth sity modalities respond shift conven throughout japan leveraging insight knowhow areas ods yet found reason cancer remains one tional treatments based characteristics common many biggest causes death today area oncology patients treatment personalized ahead preventing heat disorders currently many unmet medical needs one otsuka endeavor engage research development order otsuka group conducts educational activities people still relatively unknown otsuka pharmaceutical engaged groups focus areas based track record developing provide innovative therapeutic drugs early possible ages children seniors raise awareness activities prevent treat heat disorders company anticancer agents administered orally importance replenishing hydration electrolytes employees visit sites give seminars importance time widely available anywhere world years since term heat disorders hydration electrolyte replenishment based research otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report foundation value creation otsuka group csr society results laboratory area ion supply rehydration drinks supports organizing activities com people drinks seminars mainly target athletes coaches construc mittee awareness hidden dehydration works tion workers factory workers people work hot con raise awareness ways prevent treat dehydration otsuka group believes creation innovation sustained company growth come activities diverse ditions elderly people risk heat disorders becomes critical range employees free openminded workplace environment end aim foster corporate culture addition otsuka pharmaceutical factory sells oral rouses appetite creativity invest development human resources also actively promote diversity workforce well establishing safe working environment also make efforts realize fair hiring evaluation womens health promotion employees respecting human rights women continue play active roles society envi ronment needs established women remain active time engage childraising nursing care development human resources deal health issues however profes sional personal lives often disrupted abnormal bodily rhythms anxieties physical condition particu basic policy lar care receive midlife transitional period point history innovation always generated people attracting talented personnel developing flourishing time significant physical mental change impact otsuka group would like continuously create innovation abilities individual continuously womens healthy life expectancy otsuka group implements initiatives aimed helping women lead healthy active approach lives including seminars development products etc heath seminar alongside medium longterm business investments develop demonstrate respective skills also development nextgeneration executive human resources established open recruitment system selfassessment essential constantly achieve creative innovative system purpose enhancing capabilities sustained growth middle longer term well employee groupwide initiatives significant growth corporate value launched otsuka pharmaceutical human resources depart otsuka global academy human resource development program ment employs system following opinions voiced otsuka health comic library aim early identifying nurturing talented person employees holding individual meetings every employee otsuka health comic library helps children nel underpin development next generation also making efforts maximize development deepen interest understanding bodies executive human resource development programs senior lead global human resources organizational capabilities work health published every year since ership program middle leadership program produced introduction new system centrally manage hr infor celebrating th anniversary one volume run inhouse across otsuka group also aims mation global level employees worldwide published every year japan medical association japanese realize effective hr development collaboration play active role otsuka pharmaceutical factory society school health supervise japan pediatric association external agencies program emphasizes handing working enhance management skills leaders recommends donated approximately ele corporate culture seeks identify kind candidates implementation degree feedback system mentary schools libraries nationwide furthermore compar required lead otsuka group future end department managers receive multifaceted feedback ative table made compare course study used may employees group participated multiple people differing positions relationships reading material children also teaching program area supporting selfdirected learn system otsuka group discloses advance conditions certain otsuka health comic library posting job appoints required number people among aid science health classes held health educa ing launched oga selflearning syllabus applied employees satisfy requirements apply directly company tion workshops elementary school nurses school platform otsuka group employees utilize find infor offering position transferred expectations parties agreement open recruitment system utilized person working otsuka group officials since propose heath education using otsuka mation learning english improving business skills companies japan aims boost employee skills motivation invigorate interaction otsuka group employees health comic library among things building educational framework system employees provide information human resources depart httpswwwotsukacomjpcomiclibrary japanese reflects characteristics group companys business ment current work duties offer opinions suggestions regarding workplace describe career plan aspirations selfassessment system member diverse workforce continue implemented yearly goal developing employee skills assigning disaster relief employees right jobs improving workplace environment light obligation company handles items needed emergencies iv solutions pharmaceuti diversity cals foods beverage actively engage disaster relief activities disaster victim assistance basic policy otsuka group actively promotes diversity based belief constantly pursuit innovation endeavoring estab activities wide range employees advances lish workplace environment brimming diversity innovation globalization accordingly company otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report foundation value creation otsuka group csr society approach daycare centers located within business premises help approach since concept diversity still yet employees balance childrearing work main otsuka group companies health declaration reassuring workplace otsuka chemical example opened take japan otsuka groups top management con initiatives include formation cancer patient strives create workplace environment condu anzen dojo experiencebased safety training center tinued actively promote diversity example hosting employment support team taiho pharmaceutical company cive maintaining improving health employees center runs training sessions group employees employ womens forum based thinking develops sells anticancer agents team comprised part initiative otsuka holdings engages activities ees overseas affiliates third parties aim efforts diverse workforce made different nationalities human resources department occupational nursing aimed improving health employees collaborating improving safety awareness classroom instruction races ages gender disabilities sexual orientation needed staff aims create workplace employee suffering otsuka pharmaceutical health insurance association simulations past accidents center reaffirms experience group create innovative products ideas drive cancer disease continue work still medical professionals charge health manage failure safety awareness heightens sensitivity danger company growth receiving treatment establishing support framework ment company one activity hosting health develops ability anticipate things one step ahead otsuka group proclaimed promotion diversity company recognized excellence award seminars group employees families held recognition activities improve health safety educa otsuka group global code business ethics category outstanding initiatives help cancer japans major cities nationwide provide information tion establish safety culture otsuka chemical received became signatory womens empowerment principles patients balance treatment work groups initiatives health introduction health th responsible care excellence award japan chemical weps set corporate principles jointly developed furthermore heartful kawauchi established insurance association information improve industry association ungc un women offer guidance tokushima special subsidiary otsuka pharmaceutical health employees families another activity empower women workplace subsidiary provides place disabled people fully groupwide tokushima health project known tokj order lengthen careers diverse workforce demonstrate capabilities started theme project creating lively enhanced childcare nursing care systems womens empowerment principles cheerful workplace alleviating risk lifestyle diseases united nations global compact otsuka group companies opened three united nations entity gender equality empowerment women project kicked two approaches improving health employees susceptible metabolic syndrome tokushima area majority otsuka group employ external recognition ees live work raising awareness health issues platinum kurumin kurumin platinum kurumin otsuka pharmaceutical area overall project recommends walking exercise ministry health labour welfare tokyo stock exchange factory taiho pharmaceutical offers guidance healthy eating system whereby ministry health labour welfare certifies kurumin otsuka pharmaceutical companies meet certain standards formulating notifying others furthermore perspective creating safe tokushima health project tokj action plans based act advancement measures support raising nextgeneration children external recognition platinum kurumin certification kurumin certified companies carried higherlevel initiatives excellent corporation health certified otsuka holdings management otsuka pharmaceutical otsuka pharmaceutical factory taiho phar ministry economy trade industry nippon kenko kaigi eruboshi otsuka chemical grade top rank maceutical otsuka electronics ministry health labour welfare system recognizes corporations practice jimro otsuka wellness vending exceptionally good health management system certifies companies meet certain standards recog nizes efforts empower women workplace act promote active participation women workplace seminadeshiko selected otsuka holdings ministry economy trade industry tokyo stock exchange limited otsuka holdings otsuka pharmaceutical quality system selecting companies conform nadeshiko brand encouraging womens success workplace build sustainable society otsuka group seeking sustainability addressing environmental social issues striving diversity management selection award otsuka pharmaceutical establish quality assurance structure reassurance safety every stage value chain ministry economy trade industry system recognizes companies improved corporate value diversity management production rd procurement sales quality control health safety basic policy research development otsuka group recognizes mental physical well committed creating safe workplace environment every employee indispensable realizing continuously implementing initiatives maintain improve shared corporate philosophy otsukapeople creating health employees ethical considerations concerning appropriate rd new products better health worldwide end use experimental animals verify efficacy safety related laws ordinances guidelines striving uphold rd times necessary otsuka group complies scientifically valid methodologies ethical considerations otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report foundation value creation otsuka group csr society viewpoints animal protection welfare including experiment committee evaluates whether proposed animal partners sent back responses assess business identify potential risks take countermeasures lives animals preservation environment experiment plan appropriate based rs principles partners respect legal compliance activi principle purchase raw materials multiple companies safety experimenters replacementavoidance replacement animal use ties regarding human rights labor environment also take environmental considerations account inhouse management system developed reductionminimization number animals used anticorruption measures providing feedback example otsuka pharmaceutical collaborates ecom implemented rules experiments involve animals refinementminimization animal suffering based encouraging csr procurement merce department make suggestions environmentally established animal experiment committee properly conduct researcher education internal inspections evalu moreover order ensure stable supply products friendly packaging carry animal experiments breeding animal ations implementation experiments involving animals perform risk assessments key raw materials advance questionnaires sent business partners correspond predefined criteria ethical considerations research using humanderived specimens otsuka group sourcing procurement vision policy conducting research using information specimen col credibility research committees examining based corporate philosophy otsukapeople creating new products better health worldwide global csr standards otsuka group lected human body tissues blood research plans significance goals research personal conduct sourcing procurement activities contribute building sustainable society peoples health improvement qol otsuka strive provide products sufficient quality innovative reliable safe otsuka group complies laws guidelines conducts information management system research progress status scientifically medically appropriate research consider research outcomes standpoints ethical scientific relationship suppliers consideration society ation ethics group company establishes committees validity protection personal information build relationship trust suppliers within value achieve sustainable society fulfill social responsibility chain open fair communication aim mutual sustain human rights labor environment support local communities include outside members ensure appropriateness able growth compliance supplier selection criteria abiding laws regulations thoroughly eliminate select fair transparent companies suppliers compre unfair transactions behave high ethical standards considerations research using pathogenic microorganismsgenetically modified hensively evaluating quality q cost c delivery business stability organisms experiments using genetically modified organisms accidents toward consideration environment production quality control use pathogenic microorganisms research samples may setting internal rules examination contain otsuka group complies laws ordi safety committees screening committees nances works toward prevention experimentrelated basic policy duty healthcare company always put customers characteristics business lines namely pharma ethics development first pursuing product quality safety otsuka group ceuticals foods beverage chemicals cosmetics established production quality control system suited development pharmaceuticals confirm safety human rights personal information otsuka group imple effectiveness candidate compounds conducting clinical ments clinical trials compliance ethical principles approach trials cooperation healthy individuals patients standards including ichgcp international standard otsuka groups production quality safety control sys business established global product quality policies recognizing importance ethical considerations toward implementation clinical trials pharmaceutical products tems comply legal requirements governmental area addition product quality also aim industry standards including japans pharmaceutical medical improve quality clinical practices operations devices act pmd act japans food sanitation act handle clinical data constantly making improvements group also working acquire international certifications globally managing quality benchmarks nutraceutical procurement iso quality iso medical devices business utilize global network draw guidelines iso fssc food safety furthermore order establish benchmarks monitoring quality control activities basic policy ensure thorough quality control employ traceability strive constantly improve quality mutual knowl otsuka group together business partners aims legal compliance environment protection system covering stages product lifecycle raw edge inspection owing differences systems regula contribute building sustainable society promoting human rights material procurement production distribution sale tions country region encourage csr procurement takes consideration factors groupwide global production meetings held regularly plants acquire international standards iso share various issues case examples related production fssc iso environment also perform approach plants order provide latest information pro internal audits plants periodic basis otsuka group engages business activities safe healthy relationships formulated share duction control prevent issues occurring addition inquiries products customers reliable socially acceptable compliance laws business partners groupwide otsuka group sourcing pro provide regular training relevant employees health place framework improves value regulations across entire value chain commencing curement vision policy takes account factors safety gmp environmental protection food safety products specifically confirm product quality dealings business partner perform screening human rights labor issues environment anticorruption compliance iso standards departments product lot manufactured checks ensure quality raw materials guarantee measures also formulated sourcing procurement major group companies operate global scale analyze returned item compare products stable procurement also conclude basic transaction agree guideline embodies provisions policy plan also established operate global quality assurance sys storage plant analyze cause issue come ment advance case new supplier transactions hold information sessions future business partners tems instance global product quality meeting held future countermeasures determined carried due diligence conduct surveys business partners using csr otsuka pharmaceutical attended around good manufacturing practice hand seeking mutually sustainable development fair procurement selfassessment questionnaire provided un people including managers quality supervisors discuss equitable transparent procurement establishment global compact network japanin quality issues future initiatives pharmaceutical otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report foundation value creation otsuka group csr society sales alike periodically share details inquiries specific opin focusing related laws regulations inquiries ions users product safety information sales opinions customers also submitted relevant depart basic policy staff safety control departments quality assurance depart ments feedback reflected future product developments believe otsuka group obligated provide high suitable legally compliant promotions advertising ments also analyze inquiries receive customers improvements example taiho pharmaceutical adopted ervalue products services customers engaging communicating customers appropriate manner take steps improve products provide example new specifications reduce sharpness edges otsuka pharmaceutical received inquiries meptin aero individual cases exterior cardboard packaging tiovita approach pharmaceutical business sol inhaler used treat asthma attacks discovered series customers would cut fingers open product failed spray function properly mainly ing product otsuka group expanded jpma promotion code standards report regulatory authorities develop foreign substances entering inhaler inquiries defective products returned items prescription drugsa code behavior healthcare profes revise various documents established system mouthpiece dose counter would tick analyzed quality control departments compared sionalsto formulate code practice allows us constantly perform pharmacovigilance pv user failed press far enough result made products storage consider countermeasures group companies effort engage appropriate collabora global level collect assess product safety information changes products labelling made improvements light reason defect tion based relationships trust stakeholders includ including side effects way continue swiftly provide internal structure otsuka group makes every effort daily basis ing medical practitioners given clarification results monitoring medical institutions etc make nutraceutical business dedicated departments conscientiously swiftly respond customer inquiries relationships pharmaceutical companies healthcare sure activities continue without hitch also implement product line group companies handle feedback manner easy understand instance organizations matter social responsibility striving training every year relevant personnel example otsuka customer inquiries hold periodic employee training sessions otsuka pharmaceutical leveraging use artificial ensure adherence standards order fulfill responsibility pharmaceutical addition aforementioned training intelligence ai provide customers even better quality pharmaceutical company ensure practice proper company conducts annual training related pv employees service ai system offers common highpriority medical care based ethics patientoriented commitment based thinking every employee accountable responses based nature customers inquiry product sprays even dose furthermore addition abiding legislation country ensuring safety pharmaceutical products counter fails tick user enables operators respond quickly accurately example japan japans pharmaceutical medical devices good quality practice press way inhaler good vigilance practice reason included easytoread act pmd act engage quality control postmanufac pharmacovigilance instructions outside inhaler asking users press way turing safety control accordance gqp gvp measures counterfeit drugs counterfeit drugs become issue international collaborating market surveillance agencies industry bodies community fail provide expected thera governments making effort ensure patient peutic effect put patients health life risk safety make sure pharmaceuticals reach hands combatting counterfeit drugs otsuka launched global patients appropriate distribution channels guar product security team also involves overseas group compa antee product quality nies prepare structure deal countermeasures pharmaceutical product deceptively represents authenticity origin declaration customercentric commitment drugs contain ingredients shown label contain active ingredients shown label corporate philosophy inculcate values employees approach nutraceutical business consumer products business spirit corporate philosophy otsukapeople creating new grown business drawing upon power highly products better health worldwide otsuka group companies diverse workforce remain committed fostering social similar fashion pharmaceutical business estab moreover otsuka pharmaceutical develops products provides innovative products services contribute reward business mindfulness employees may stay abreast ing healthier lives people everywhere aiming maintain trust prevailing values true customer needs order create new catego lished dedicated unit comprising multiple departments deliver health value based scientific grounds estab customers society ries products services review marketing plans sales promotion materials prod lished scientific affairs department gather dissemi interactive communication customers ucts nutraceutical consumer products businesses nate information products related knowledge policies applying knowledge knowhow accumulated years commitment leaders research business conduct mutual communication activities ensures marketing sales promotion activities latest academic information department also holds monthly conduct daily business constant attentiveness including seminars factory tours online communications encour appropriate comply laws regulations information sessions employees patients customers truly desire continue uphold otsukas age people become aware informed health culture actualization creativity company involved also established points contact inquiries consultations aspects health treatment illnesses maintenance feedback enhance products services communication patients medical professionals customers promotion healthy lifestyles dedicated becoming coordination cooperation rapid problemsolving indispensable company contributing better health quality life healthrelated company always put patients consumers people around globe first prioritizing safety products issues come light otsuka group recognizes enhancing mutual communi customercentric commitment clearly express stance corporate governance marshal resources may quickly efficiently provide cation customers responding opinions undertaking initiatives basic policies dictate fulfill social responsibilities solutions develop everbetter products services sincerity improves value products pharmaceutical business order minimize prob honest trustworthy dialogue customers business collaborators october employees local communities shareholders extension contributes peoples health society local lems risks associated product quality safety transparent fair timely decisionmaking communities published declaration usability experienced patients healthcare professionals otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report foundation value creation otsuka group csr environment environment thirdparty verification ghg emissions order improve transparency reliability environ ghg emissions throughout value chain fiscal healthier planet mental data otsuka group subject verification emissions scope greenhouse gas ghg emissions scopes categories categories aiming indispensable company contribute health global people otsuka group scope thirdparty organization also implement initiatives aimed understanding improving category scope policy engages business activities voluntarily positively continuously creativity considering global emissions use trends emissions continue expand scope sold products environment value chain committed shaping sustainable society verification enhance reliability data thousand tonsco scope scope direct emissions scope indirect emissions energy sources category otsuka group global environmental council scope indirect emissions emissions purchased goods services companies otsuka pharmaceutical otsuka pharmaceutical factory taiho pharmaceu tical otsuka chemical otsuka foods group global companies contribute health demands global society deepening understanding people worldwide otsuka group works sincerely reduce recognition environmental problems environmen resource circulation impact global environment busi tal education employees enhancing collabora fy goal reduction simple incineration landfill compared fy nesses hopes contribute creation sustainable tion group companies society protect nature future earth aiming achieve sounded materialcycle society working improve resources usage efficiency reduce gener otsuka group global environmental councilcompris ation waste promote r reduce reuse recycle initiatives achieve final waste disposal volume close zero ing director otsuka holdings executive officers effort realize zero emissions inhouse definition recycling rate least council organization group company secretariatformulated otsuka group environmental policy guidelines advances initiatives groupwide coordinator initiatives aimed zero emissions resource recycling rate final disposal amount environmental management collaboration otsuka holdings director tons otsuka group companies otsuka group companies carry material recycling otsuka group identified climate change resource thermal recycling generated waste required circulation water conservation csr materiality secretariat fiscal group companies japan achieved zero environmental initiatives kicked deliberations emissions recycling rate also reduced otsuka holdings formulation longterm environmental vision consis otsuka pharmaceutical total waste volume around tons yearonyear tent principles united nations global compact reduction group continue work bringing information disclosure global standards setting waste minimize disposal volume activities mediumterm environmental targets specific action plans council members enhance efficient use resources across businesses slated launch otsuka otsuka taiho otsuka otsuka otsuka th e p ur ec oe fs ti hn eg r man ad l er neu ers ge gf ew na es rt ae ea ds fr ra ow ina ct ie nr eia rals io n n og f r wed ai se tn et looking ahead strengthen practice environmen pharmaceu pharmaceu pharmaceu chemical warehouse foods major consolidated subsidiaries japan tical tical factory tical tal management meets social responsibilities water conservation fy goal improvement water use efficiency compared fy climate change fy goal reduction co emissions compared fy otsuka group identifies water resources csr materiality environmental initiatives along evaluating waterre lated issues much water used key production sites around world otsuka group also encourages regionally appropriate management efficient water usage goal conserving improving water resources recognize otsuka group conducts business global scale faces significant risks impact climate change accordingly formulating longterm reduction targets action plans achieving targets moreover aiming realize carbonfree society promote thorough energysaving measures endeavor alleviate impact evaluating water risks production water usage water use efficiency environment use renewable energy sites thousand thousand million otsuka group conducting water risk assessment initiatives energy use optimization co reduction evaluation production sites using water risk evalua tokushima prefecture production sites group emissions across group include use joint crediting tion tool aqueduct developed world resources insti concentrated otsuka chemical otsuka pharmaceutical mechanism jcm installation highly efficient equip tute wri since understand reduce impact factory supply electricity steam neighboring group com ment pt otsuka indonesia waterrelated business activities panies use cogeneration systems installed initia system work developing countries reducing greenhouse gas emissions calculated otsuka group consolidated subsidiaries companies included top tives overseas promote efficient energy use reduce co w jah pi ac nh result reduction assessed contribution partner countries energyderived co emission producers outside japan japan otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report foundation value creation otsuka group csr governance governance initiatives strengthen corporate governance levels director remuneration corporate gover establishment otsuka holdings co ltd nance issues reports board directors term directors set one year decision adopt directors retirement benefits system committee consists ceo director charge admin corporate officer system adopted two outside audit supervisory board members istration outside directors currently three ceo three outside audit supervisory board members stock options performancelinked remuneration introduced serves chair committee addition improving management soundness work improve corporate ethics work stock publicly listed december policy first mediumterm management plan announced appropriate risk management two outside directors three outside audit supervisory board members e audit supervisory board member audit second mediumterm management plan announced supervisory board three outside directors two outside audit supervisory board members otsuka group global code business ethics established audit supervisory board members attend express opinions corporate governance corporate governance guidelines established internal whistleblowing system established externally otsuka holdings major meetings board directors monitor legality group companies three outside directors three outside audit supervisory board members soundness management shown performance effectiveness board directors evaluated basic position corporate governance stock options conditional progress mediumterm management plan duties directors audits performed audit supervisory introduced otsuka holdings committed promoting sustainable increase business partners employees local communities sharehold corporate governance guidelines revised board core process striving improve corporate governance committee established corporate value medium longterm realizing ers ongoing dialogue company articulates basic effectiveness board directors evaluated based questionnaire completed effectiveness audits audit supervisory board members also directors audit supervisory board members corporate philosophy otsukapeople creating new products approach corporate governance corporate governance reporting meetings held outside directors outside audit supervisory board share information exchange opinions appropriate members improve understanding groups management business better health worldwide meet commitment guidelines two female directors relevant departments internal audit department internal corporate governance guidelines revised adopts basic policy making transparent fair timely control department administration department finance restricted stock compensation plan introduced decisions fulfilling corporate social responsibility living corporate governance guidelines accounting department well accounting auditor expectations stakeholders including customers httpswwwotsukacomencompanygovernancepdfguidelinepdf corporate organization company adopts statutory auditor system f evaluation effectiveness board directors overview corporate governance structure company board directors audit supervisory january february every year company con board also engages accounting auditor articles ducts questionnaire survey directors audit board directors also includes outside directors governance system quick reference march incorporation stipulate number directors shall supervisory board members based outcomes advances execution management plans supervises form organization company audit exceed number audit supervisory board survey company performs examination evaluation companys management also assumes roles responsibili supervisory board members shall exceed five board directors meeting march following review ties enhance profitability capital investment efficiency board directors company attorney order promote sustainable growth company outside directors independent directors b board directors summary evaluation fiscal increase corporate value medium longterm board directors convenes month regularly results analysis evaluation overall effective term directors one year company secures soundness establishes solid holds extraordinary meetings necessary make important ness board directors fiscal summarized audit supervisory board corporate governance structure living social expectations members business decisions supervise execution operations board members expressed opinion collab ensuring audit supervisory board members oration outside directors audit supervisory outside audit supervi independent directors independent board directors audit sory board members c director selection criteria board needs enhanced confirmed meetings directors performance duties collaboration accounting auditor deloitte touche tohmatsu llc company aims become indispensable contributor audit supervisory board outside directors accounting auditor well internal audit department peoples health worldwide targeting sustained growth well opportunities exchanging opinions man enhanced corporate value medium long term help agement outside directors held regularly achieve goal also ensure diversity among directors serve improve communication ahead shareholders meeting company appoints adequate people directorspeople result revising information provided board electsdismisses electsdismisses electsdismisses insight advanced expertise extensive experience con members improvements regarding meetings consults ducive realizing maintaining appropriate effective board directors managed assessed favorably corporate board directors operational audits audit g co ov mrn ia ttn ec ee recommends directors including outside directors accounting audits u ap ue dr itv oi rs inry cl ub ina gr corporate governance particularly internal directors confirmed deliberations meetings appointsdismisses outside members comprehensively evaluate experience expertise insights enhanced ahead taking account opinions attributes candidates ensure quali board members president representative cooperates director ceo cooperates ties required implementing groups corporate philosophy confirmed system monitoring execution code business ethics corporate strategies corporate strategies business needs instructs reports accounting audits accounting auditor enhanced even though improvements made internal audit department corporate governance committee believe assessments indicate board cooperates seeking increase managements transparency objectiv directors functioning properly terms effectiveness ity company established corporate governance committee strive make improvements regarding issues high approval meetings prior material matters groups boards consultation february advisory body board directors lighted evaluation examination increase boards management corporate ex post facto guidance auditors reports committee discusses deliberates nomination effectiveness make every effort deepen corpo directors audit supervisory board members structure rate governance company subsidiaries shareholders meeting board directors audit supervisory board members etc otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report foundation value creation otsuka group csr governance g independent directors auditors otsuka group companies past established h internal audit department assess internal controls basic approach internal con selecting outside directors outside audit supervisory independence standards outside directors order ensure companys internal audit department reports directly trol system establishment described corporate board members company looks individuals great independence standards set corporate president department regularly conducts audits based governance report submitted tse deal knowledge extensive experience various fields governance guidelines also apply outside audit internal audit rules verify operations exe company requires candidates ability adequately supervisory board members furthermore given outside cuted appropriately efficiently regard assets j accounting audit exercise management oversight functions fair objec directors outside audit supervisory board members satisfy business general company affiliated companies otsuka holdings signed auditing agreement tive monitoring supervision auditing management requirements independent directorsauditors prescribed department submits audit reports president directors auditing firm deloitte touche tohmatsu llc accounting auditor neutral objective viewpoint addition requiring tokyo stock exchange tse company registered audit supervisory board members need audit companys accounts fair impartial stance outside directors involved business execution tse improvement indicated department recommends actions certified public accountants audited companys taken afterward confirms status implemen accounts tsutomu hirose koichi niki ichiro matsunaga rationale selection outside directors auditors tation order optimize business execution department assisted certified public accountants times attended fy also shares information cooperates audit supervisory three people certified public accountants name rationale selection dbo ira er cd rf vu id soit r b ou ap dr board members accounting auditor audited companys accounts done continuously meeting meeting less seven years therefore omitted description mr matsutani giving effective advice companys managers neutral internal control department expert perspective outside director abundant experience extensive knowledge yukio medical welfare field well expertise healthcare industry since risk companys internal control department handles internal k succession plan matsutani conflict interest visvis general shareholders moreover company believes mr mat controls regarding financial reporting company order identify talented personnel early systematically sutani suitable independent director affiliated companies department formulates rules man develop nextgeneration executives equipped qualities company anticipates given abundant experience extensive knowledge corpo rate manager well expertise pharmaceutical industry mr sekiguchi able uals pertaining internal controls provides training skills required corporate philosophy otsuka holdings outside ko directors sekiguchi give effective advice appropriate companys managers neutral expert perspec ensures employees thoroughly understand operational rules continuously builds implements nextgeneration executives tive outside director since risk conflict interest visvis general shareholders moreover company believes mr sekiguchi suitable independent director department works cooperation internal audit development program regularly reports progress department continuously monitor status operations board directors company anticipates given abundant experience track record insight corpo rate manager well ample experience expertise network food industry mr aoki thus establishing system executives reliably yoshihisa human resource development p able provide beneficial shrewd advice companys management objec aoki tive expert perspective outside director risk conflicts interest general shareholders company believes mr aoki suitable independent director remuneration directors auditors mr sugawara specialized knowledge certified public accountant well abundant business experience company determined able use experience hiroshi expertise audits company since risk conflict interest visvis general sugawara shareholders moreover company designated mr sugawara independent audit remuneration system directors auditors designed management plan combining multiple conditions earnings supervisory board member company attracts retains talented personnel achievement based earnings indicators rd medi outside attorney ms wachi wellversed corporate legal affairs company deter strongly motivates perform duties thereby contrib umterm management plan audit yoko mined able use experience expertise audits company since supervisory wachi risk conflict interest visvis general shareholders moreover company uting sustained improvement groups earnings board members designated ms wachi independent audit supervisory board member corporate value b remuneration directors subsidiaries oper mr takahashi held major positions internal control departments many years ating companies kazuo abundant experience corporate management company determined director remuneration company hold remuneration directors subsidiaries operating compa able use experience expertise audits company since takahashi risk conflict interest visvis general shareholders moreover company designated ing company nies determined based duties responsibilities mr takahashi independent audit supervisory board member remuneration directors otsuka holdings holding com execution business based group strategies formulated number board directors meetings audit supervisory board meetings attended outside director yoshihisa aoki listed newly appointed th pany consists fixed remuneration according title posi otsuka holdings well duties responsibilities involving general meeting shareholders held march tion bonuses linked performance provide shortterm formulation strategies operating company incentives stockbased compensation provides strengthening corporate governance exceed independence standards outside directors corporate governance guidelines medium longterm incentives beginning fiscal cap director remuneration resolved general meeting replacing stock options restricted stockbased shareholders note restricted stockbased compensation company determines outside director independent none following applies compensation system incentive plan achieve sustained system newly implemented fiscal also apply person relative within second degree kinship outside director currently past three fiscal years man growth medium longterm earnings corporate value roughly directors excluding outside directors aging director executive officer executive operating officer important employee executive company one companys subsidiaries restricted stocks issued system part com groups major subsidiaries company outside director belongs executive one transactions otsuka group amount pensation system reflects attainment mediumterm transactions fiscal year within past three fiscal years exceeds consolidated net sales either company outside director legal accounting tax expert consultant received remuneration exceeding million per fiscal year directly otsuka group excluding remuneration companys outside director fiscal year within past three years amount donation nonprofit organization outside director belongs executive otsuka group exceeded million total past three fiscal years amount exceeds income nonprofit organization otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report foundation value creation otsuka group csr governance c remuneration auditors company total remuneration officer category total remuneration evade payment taxes group also endeavors parency trust dealing tax authorities worldwide type number applicable officers audit supervisory board members essentially paid appropriately disclose information ensure degree trans basic remuneration variable components based total total remuneration type number earnings co atf ef gic oe rr n er e mr eam ilt c liu oo nn remb tu ia ons ni ec ra cc h oa pm r tgoi f il e l u si tn sn c k bonus reo r bf w tf c u iai oehc nsi ne iv ecr e rs risk management directors excluding basic policy outside directors otsuka group carries risk management supervi management efficiency controlling risks inherent audit super sion top management based recognition pursuing business activities key enhance corporate value visory board members excluding risk management system outside audit supervisory establishing risk management system otsuka group others leveraging controls put place risk board members put place risk management policy set risk management department risk management committee outside directors management committee comprising director charge assesses comprehensively manages risks jeopardize administration president representative director chair enhancement groups sustained corporate value compliance approach basic policy individually assess risks businesses risk could pose risk within organization training related legal compliance forms cornerstone business activi aim achieve sustained growth along earning trust management officer performs analyses evaluation formu topics corruption prevention protection ties otsuka group possesses high ethical standards customers conducting business activities honestly lates executes action plans aim meeting objec human rights based otsuka group global code busi tives targets organization periodically ness ethics also part approach also regularly hold approach implements employee training reference events drills prepare unexpected contingencies like disasters otsuka group established otsuka group global code regular meetings held progress initiatives business ethics openly publish information country shared compliance officer otsuka hold business continuity planning management stance initiatives line code website ings also visits overseas group companies gather informa otsuka group business continuity plans bcp place bcm standpoint organization equipped form message president otsuka holdings tion offer suggestions improvements may made ensure group continues operate effectively infallible business continuity capabilities collaboration also drawn otsuka group global anticorruption due diligence policy also force group com possible maintain stable supply products even mainly otsuka pharmaceutical otsuka pharmaceutical policy represents stance preventing corruption panies conduct due diligence new business partners largescale earthquakes disasters strike factory taiho pharmaceutical otsuka warehouse sites worldwide accordingly continue conduct purpose assessing risk related corruption perspective business continuity management bcm otsuka making every effort strengthen countermeasures business activities based strong sense ethics hold otsuka holdings leading group companies holdings group companies jointly constructed systems otsuka group whole continue universal training sessions every year based taken steps establish internal whistleblowing systems groupwide business continuity framework gradually business activities best possible guarantee stable prod content aforementioned code policythey accessed within company external loca expanded scope framework since acquiring iso uct supply even times disaster major attended employees subsidiaries prepare materi tion offices attorneys rules allow certification august production stable supply group companies jointly conducted desktop simulation drill als english chinese indonesian addition japanese whistleblowing fulltime employees also con medicinal products beverages foods acquired assumption earthquake epicenter directly furthermore details training sessions reported tract dispatched parttime employees rest certification stable supply infusion solutions april tokyo drill provided opportunity test regularly board directors otsuka holdings internal assured knowing information followed stable supply anticancer drugs may collaborative framework based topic ensuring stable compliancerelated audits implemented periodically reports strictly managed prevent negative repercus acquisition iso certification demonstrates product supply group company results reported board sions information related internal whistleblowing systems directors initiatives overseas compliance officers major group companies reported regularly board information security appointed group companies asia directors meetings otsuka holdings striving raise level constantly improve compre construct data otsuka group established man hensive security across group set otsuka group infor agement system protect sensitive personal information mation security committee facilitate sharing uptodate customers acquired personal information protection tax compliance security information examination specific security management system privacymark certification information measures order counter risk cyberattacks security management system isms certification busi basic policy otsuka group employs number measures arranging nesses appropriate otsuka also established eu general otsuka group operates countries around world contributes local economy countries regions system security audits external specialists diagnosing website data protection regulation compliance policy concern recognizes appropriate payment taxes accordance otsuka group fulfills tax obligations accordance vulnerabilities conducting drills related targeted email attacks ing general data protection regulation gdpr part group relevant laws regulations country region otsuka group global code business ethics monitoring posts social media addition group wide initiatives information security conducts regular emergency drills focus core systems approach otsuka group complies aforementioned code international taxation rules submitting tax declarations correctly ethics tax policies countryspecific laws tax conventions paying corporate tax engaging transactions designed otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report foundation value creation directors audit supervisory board members march left noriko tojo yoshihisa aoki sadanobu tobe yukio matsutani yoshiro matsuo ko sekiguchi ichiro otsuka tatsuo higuchi yozo toba yuko makino hiroshi sugawara shuichi takagi yoko wachi atsumasa makise kazuo takahashi masayuki kobayashi directors chairman representative director president representative director ceo senior managing director outside director outside director outside director ichiro otsuka tatsuo higuchi yoshiro matsuo yukio matsutani ko sekiguchi yoshihisa aoki apr joined otsuka pharmaceutical factory inc mar joined otsuka pharmaceutical co ltd apr joined otsuka pharmaceutical co ltd apr intern pediatric department st lukes international hospital apr joined mitsubishi corporation apr joined itochu corporation june e xecutive director director consumer products development june enior managing director otsuka pharmaceutical co ltd jan v ice president associate general manager general affairs oct j oined ministry health welfare present day ministry may joined boston consulting group june executive officer itochu corporation division otsuka pharmaceutical co ltd pharmavite department otsuka pharmaceutical co ltd health labour welfare jan g eneral manager sterrad business division johnson johnson apr anaging executive officer president food company itochu june anaging director responsible consumer products publicity nov e xecutive deputy president executive director otsuka june v ice president general manager general affairs department aug irectorgeneral health policy bureau ministry health labour medical k k present day johnson johnson k k medical corporation promotion development division otsuka pharmaceutical co ltd pharmaceutical co ltd otsuka pharmaceutical co ltd welfare company apr ember board senior managing executive officer president dec e xecutive director research development otsuka pharmaceuti june e xecutive director responsible us business otsuka pharmaceu nov enior vice president general manager general affairs aug director national sanatorium tama zenshoen nov p resident representative director janssen kyowa co ltd food company itochu corporation cal factory inc tical co ltd department additional responsibility legal affairs apr president national institute public health present day janssen pharmaceutical k k mar administrative officer itochu corporation current position may representative director otsuka pharmaceutical factory inc june p resident representative director otsuka pharmaceutical co external relations otsuka pharmaceutical co ltd dec v ice president international university health welfare july chairman director janssen kyowa co ltd june outside director arata corporation current position dec e xecutive deputy president representative director otsuka ltd july anaging director corporate administration otsuka holdings co current position oct supreme advisor janssen kyowa co ltd mar outside director otsuka holdings co ltd current position pharmaceutical factory inc june executive director otsuka pharmaceutical co ltd ltd mar outside director otsuka holdings co ltd current position jan r epresentative director dia japan present day sh dia japan dec p resident representative director otsuka pharmaceutical july p resident representative director ceo otsuka holdings co mar enior managing director corporate administration otsuka apr utside director nic corporation present day solasto corpora factory inc ltd current position holdings co ltd tion current position july executive director otsuka holdings co ltd dec executive director otsuka chemical co ltd jan e xecutive director otsuka medical devices co ltd current mar outside director kenedix inc june e xecutive deputy president executive director otsuka holdings feb p resident representative director otsuka pharmaceutical co position mar outside director otsuka holdings co ltd current position co ltd ltd current position mar enior managing director otsuka holdings co ltd current june r epresentative director otsuka pharmaceutical factory inc position vice chairman representative director otsuka holdings co ltd mar e xecutive director otsuka pharmaceutical co ltd current position chairman otsuka pharmaceutical factory inc current position chairman representative director otsuka holdings co ltd current position executive director cfo executive director executive director yuko makino sadanobu tobe atsumasa makise apr joined otsuka pharmaceutical co ltd apr enior managing director representative director shinko foods dec joined otsuka pharmaceutical co ltd audit supervisory board members apr joined baxter limited co ltd present day otsuka foods co ltd june v ice president director odpi division otsuka pharmaceutical apr joined otsuka pharmaceutical co ltd july e xecutive deputy president representative director otsuka co ltd mar irector corporate finance accounting department otsuka foods co ltd june v ice president director finance department oiaa division holdings co ltd nov e xecutive deputy president representative director otsuka otsuka pharmaceutical co ltd standing audit outside audit outside audit outside audit supervisory sept v ice president director corporate finance accounting chemical holdings co ltd present day otsuka chemical co ltd june anaging director finance accounting otsuka pharmaceutical supervisory board member supervisory board member supervisory board member board member department otsuka holdings co ltd may p resident representative director otsuka chemical holdings co ltd vice president director accounting department otsuka co ltd july enior managing director corporate finance otsuka holdings co yozo toba hiroshi sugawara yoko wachi kazuo takahashi pharmaceutical co ltd july executive director otsuka holdings co ltd ltd apr v ice president director tax department otsuka holdings co june vice chairman representative director otsuka foods co ltd may chairman ceo otsuka america inc apr joined otsuka chemical co ltd oct joined chuo audit corporation apr r egistered attorney law daiichi tokyo apr j oined ebaraudylite co ltd present day ltd june chairman representative director otsuka chemical co ltd apr chairman otsuka america inc jan irector information center otsuka chemical oct j oined deloitte touche tohmatsu present day bar association jcu corporation vice president director finance accounting department june vice chairman otsuka foods co ltd mar executive director otsuka foods co ltd co ltd deloitte touche tohmatsu llc joined kajitani law offices current mar e xecutive director strategic planning ra otsuka pharmaceutical co ltd june tanding audit supervisory board member otsuka holdings co mar p resident representative director otsuka foods co ltd jan cfo trocellen gmbh feb v ice president capital management co position institute co ltd mar e xecutive director corporate finance otsuka holdings co ltd ltd current position may perating officer information system ltd current position june c orporate auditor nichias corporation nov e xecutive director general manager mar executive director cfo otsuka holdings co ltd current position nov president representative director otsuka foods co ltd executive director otsuka holdings co ltd current position department otsuka chemical holdings co june utside audit supervisory board member current position system division sunkus associates inc june executive director otsuka holdings co ltd current position ltd present day otsuka chemical co ltd otsuka holdings co ltd current position mar utside audit supervisory board member oct e xecutive director head information mar chairman otsuka foods co ltd june c orporate officer director corporate june utside audit supervisory board member otsuka holdings co ltd current position system division circle k sunkus co ltd mar executive director otsuka foods co ltd current position f hi la dn ince g c oc c lo tu dn ting department otsuka oct uts tu sik da e p dh ia rerm cta oc nu pic pa ol nco p l rt kd ing develop may e tx ac tu et giv e ffi ir ce ec hr e c ch uie stf oo mf eth r e fra na cg ism ee en executive director business portfolio dec e xecutive director corporate administration ment co ltd relations office internal control executive director executive director management accounting otsuka chemical co ltd mar udit supervisory board member otsuka e sun nvi kr uo sn coe n la tl anagement office circle k mar e xecutive vice president corporate finance pharmaceutical co ltd current position masayuki kobayashi noriko tojo shuichi takagi accounting corporate service department may e xecutive director head area franchise otsuka holdings co ltd circle k sunkus co ltd auct g j p rein se idd e na ti h ip hh oa prm haa rc meu uic sa al c io n c l pd r esent day taiho oncology ap ur g j jo oi ne ed g sho eld rsoa nn ls ea hch ms nja bp ra th ec ro r hpo ldat inio gn inc sep pr j j oi ne ed oo tsb uis kh pm ha rc mo ar cep uo tr ica l co ltd mar ot ta sn ud ki g h oa lu dd init g cs ou p e lr tv di cry u rb reo na tr p om se itm iob ne r ay r e od x uve tic ssu ii dot ei nv e c ud dri cr ite le c ko r u uh pn ee k ra vud ocf ro yi n b f l oo ar dm r da mtio en es rt e ms inc july engagement manager mckinsey company japan office aug f inance department oiaa division otsuka pharmaceutical co otsuka holdings co ltd current position sept executive director taiho pharmaceutical co ltd june director intel capital japan intel corporation ltd apr president ceo otsuka america inc aug managing director corporate development otsuka holdings co ltd july c orporate finance accounting department otsuka pharmaceuti apr p resident representative director taiho pharmaceutical co ltd feb executive director otsuka medical devices co ltd cal co ltd mp ar r c e ec xx hu ee cr c ir uu ttn ii vv ee np ddo ts ii rri eet ii h cco ttn oo rr ona ti c sh uoo k lp ao h hga ym l ia n u c gss cc ou rn rc le tn dt p cos ui rt rio enn position jap u nr g p e p ltxr r de ee sc ud cte e uivn n ret r e ad nn ni trd e p cc r ot see ipo r ir oa e nsd e ts n cu tak e ta va epm h de irr r ei mc ca ta ov rin e oc tl sl uc ka medical devices co jana ar v c st f ia eci ec c naoe l io p ir nc rr l ii crni id e sc pe po rn rvt e asr su te ie dks ep l ip tn r iis tv pi eb rd etle e dlo emr n tn e sd di oa fpb fir cu e es en one tts u ko os hu ok lua dk ip nah g pa sh r cm ora c e lu tc deti uca l may executive director otsuka america inc mar e xecutive director business portfolio management otsuka holdings aug chairman pharmavite llc co ltd current position mar executive director otsuka holdings co ltd current position otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report data section main data effect fiscal ended december otsuka adopted international financial reporting standards ifrs information fiscal ended december also presented line ifrs billions yen billions yen millions us dollars jgaap jgaap ifrs ifrs item results revenue operations selling general administrative expenses research development expenses rd ratio operating profit operating profit margin profit attributable owners company financial total assets position total equity ratio equity attributable owners company total assets roe cash flows net cash flows operating activities net cash flows investing activities free cash flows dividends annual dividend per share yen dividend payout ratio common stock number shares outstanding yearend thousand stock price shares stock price yearend yen number total persons employees japan persons outside japan persons female manager number female managers persons ratio female manager ratio e dn av ti ar n mental total co emissions tt oh su csa japan outside japan co emissions per sales ton million water usage thousand resource recycling rate item names according ifrs number employees otsuka holdings subsidiaries december sga expense jgaap presented total expense less rd expenses company believes useful investors comparing companys financial results companies nonconsolidated otsuka pharmaceutical otsuka pharmaceutical factory taiho pharmaceutical otsuka chemical otsuka warehouse otsuka foods jgaap ifrs environmental data limited past four years due change collation criteria due change consolidated fiscal year fiscal ended december transitional period covering nine months april december calculated consolidated subsidiaries otsuka group companies constitute top co emissions originating energy us dollar amounts report represent translations japanese yen solely readers convenience rate us approximate exchange rate december figures major consolidated subsidiaries japan otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report data section management discussion analysis consolidated financial results fiscal market environment eb guadecitabine development code sgi year increase mainly due increases property plant previous fiscal year net cash provided operating activities environment surrounding healthcare industry currently currently developed treatment atten equipment million yen goodwill million million yen fiscal net cash used invest experiencing period change particular aging society tion deficit hyperactivity disorder adhd acute myeloid yen intangible assets million yen deferred tax ing activities million yen due investments made introduction expensive drugs outbreaks infectious leukemia aml respectively assets million yen also decrease future including acquisition remaining shares diseases contributing everincreasing health care budgets selling general administrative expenses current financial assets million yen recor medical inc acquisition visterra inc net cash making governments japan united states fiscal year included impairment loss million yen used financing activities million yen result europe become aware costs medical treatments intangible assets trademarks marketing rights etc due liabilities dividend payments yen per share shareholders faced limited financial resources medical guidelines termination license agreement onzetra xsail generic total liabilities december million million yen total repayments noncurrent borrowings caught balance costs benefits treat name sumatriptan addition fiscal year avanir pharma yen increase million yen compared million yen result total amount cash ments penetration generic drugs reforms ceuticals inc californiabased subsidiary otsuka group million yen end previous fiscal year increase outflows investing financing activities exceeded operat drug pricing system continuing progress expensive reached agreement principle resolve united mainly due million yen current noncurrent ing cash inflows medical treatments new technologies emerging well states department justices investigation related certain contract liabilities resulting application ifrs total amount bonds borrowings december circumstances needs steadily increasing avanirs past sales marketing practices product fiscal also million yen decrease million yen exceeded total daily measures disease prevention balanced life plans nuedexta agreement principle avanir current noncurrent bonds borrowings due cash cash equivalents therefore group maintained include nutrition addition exercise rest united states contingent upon parties negotiation scheduled payment borrowings acquisition avanir financial soundness otsuka groups operations encompass two core busi execution civil criminal administrative agreements pharmaceuticals inc status groups cash flows fiscal nesses pharmaceutical business provides comprehen estimated fines damages disgorgement restitution legal along contributing factors follows sive health support diagnosis disease treatment fees interest charges may total approximately million current liabilities nutraceutical business assists people maintaining part accrued previous fiscal year total current liabilities december cash flows operating activities improving daytoday health response growing fiscal year accrued remaining million million yen increase million yen compared net cash provided operating activities fiscal amounted awareness health reconfirming strong belief selling general administrative expenses million yen end previous fiscal year million yen contributing factors importance total health care including disease prevention increase mainly due increases trade payables million yen profit taxes million yen deprecia financial position million yen contract liabilities million yen tion amortization expenses million yen impair status revenues accompanying application ifrs fiscal ment loss reversal impairment loss million yen fiscal year ended december assets current liabilities million yen share profit associates million yen increase otsuka group recorded consolidated revenues total assets december million trade receivables million yen income million yen previous fiscal year operat yen decrease million yen compared noncurrent liabilities taxes paid ing profit million yen profit year million yen end previous fiscal year current assets total noncurrent liabilities december million yen profit attributable decreased million yen noncurrent assets million yen increase million yen compared cash flows investing activities owners company million yen increased million yen decrease current million yen end previous fiscal year net cash used investing activities fiscal amounted strong growth global products new product lineup assets increase noncurrent assets due mainly increase mainly due increase contract liabilities million yen main investing activities included contributed favorably increased revenues group achieved fact group used cashonhand finance acqui million yen due application ifrs fiscal million yen payments acquisition property plant growth operating profit even actively investing rd sition remaining shares recor medical inc also decrease bonds borrowings equipment million yen payments acquisition profit attributable owners company decreased acquisition visterra inc million yen intangible assets million yen proceeds sales previous fiscal year due mainly tax reform redemption investments million yen payments equity us transient impact reversed income tax expenses current assets acquisition investments million yen payments profits excluding impact profit attributable owners total current assets december amounted total equity december million yen acquisition subsidiaries million yen decrease company current fiscal year would par million yen decrease million yen compared decrease million yen compared million time deposits payments acquisition subsidiaries previous fiscal year million yen end previous fiscal year yen end previous fiscal year decrease primarily acquisition remaining shares recor current fiscal year million yen recog decrease mainly due decreases cash cash mainly due million yen decrease retained earnings medical inc acquisition visterra inc nized income related transaction equivalents million yen financial assets result million yen payment dividends group acquired remaining shares recor medical inc million yen offset increases trade million yen profit attributable owners company cash flows financing activities transformed company wholly owned subsidiary receivables million yen inventories million yen impact due application ifrs net cash used financing activities fiscal amounted reevaluated existing shareholding contractual rights million yen million yen decrease components equity million yen main financing activities included recor medical inc accordance ifrs due stock market exchange rate fluctuations million yen proceeds noncurrent borrowings addition impairment loss million yen noncurrent assets million yen repayments noncurrent borrowings status cash flows intangible assets inprocess research development total noncurrent assets december million yen dividends paid recorded rd expenses result revising future profit million yen increase million yen com cash cash equivalents december decreased ability projections centanafadine development code pared million yen end previous fiscal million yen million yen end otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report data section consolidated financial statements otsuka holdings subsidiaries year ended december consolidated statement financial position billions yen millions us dollars billions yen millions us dollars assets liabilities equity current assets liabilities current liabilities cash cash equivalents trade payables bonds borrowings trade receivables financial liabilities inventories income taxes payable contract liabilities income taxes receivable current liabilities financial assets subtotal liabilities directly associated assets held sale current assets total current liabilities subtotal noncurrent liabilities assets held sale bonds borrowings financial liabilities total current assets net defined benefit liabilities provisions contract liabilities deferred tax liabilities noncurrent assets noncurrent liabilities property plant equipment total noncurrent liabilities total liabilities goodwill intangible assets equity equity attributable owners company investments associates share capital capital surplus financial assets treasury shares deferred tax assets retained earnings components equity noncurrent assets total equity attributable owners company total noncurrent assets noncontrolling interests total equity total assets total liabilities equity us dollar amounts report represent translations japanese yen solely readers convenience rate us approximate exchange rate december consolidated financial statements notes consolidated financial statements refer consolidated financial statements httpswwwotsukacomenirlibraryreporthtml otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report data section consolidated financial statements otsuka holdings subsidiaries year ended december consolidated statement income consolidated statement changes equity billions yen millions us dollars billions yen equity attributable owners company components equity rev ce su e sales cs ah pa itr ae l c sua rp pi lt ua sl tr se ha ru er sy r ee ra ni ne gd dm e ee n fia nss e u dr f e f ti hmn ra fe oan uic rs g u va hr al e l oa uds te hs e ett rs trc af uo nrr sre e lai ng tc oy n c eh gfl eo sw total total n r ton el rlc eno sgn ts et qo ut ia tl gross profit benefit plans com ip nr ce oh ensive reserve selling general administrative expenses balance january research development expenses profit year share profit associates comprehensive income income comprehensive income expenses purchase treasury shares operating profit dividends sharebased payment transactions finance income changes ownership interests subsidiaries finance costs result loss control nonoperating income expenses transfer components equity retained earnings profit taxes total transactions owners etc income tax expenses balance december profit year balance january changes accounting policies attributable restated balance owners company profit year noncontrolling interests comprehensive income comprehensive income earnings per share yen us dollars purchase treasury shares basic earnings per share dividends diluted earnings per share sharebased payment transactions changes ownership interests subsidiaries result loss control disposal subsidiaries transfer components equity retained earnings consolidated statement comprehensive income total transactions owners etc billions yen millions us dollars balance december profit year millions us dollars equity attributable owners company components equity comprehensive income noncon com rep mo en ae sn urt es mth ea nt sw oi fl l n eo fit n eb de br ee ncl ea fs pf li ae nd profit loss cs ah pa itr ae l c sua rp pi lt ua sl tr se ha ru er sy r ee ra ni ne gd br ee ndm ee e fe n f iia tt n ss pe u lar f e n f cti ohmn mra fe oa p na uic rs r cg eu ova h hr al e el oa ud ens te hs sa e ie vtt r es trc af ru eo nr sr sr ee e la ri ng vtc en oy n c eh gfl eo sw total total nr el rli en sg ts et qo ut ia tl financial assets measured fair value comprehen balance january sive income changes accounting policies share comprehensive income associates restated balance subtotal profit year comprehensive income components may reclassified profit loss comprehensive income foreign currency translation reserve purchase treasury shares cash flow hedges dividends share comprehensive income associates sharebased payment transactions subtotal changes ownership interests subsidiaries result total comprehensive income loss control comprehensive income disposal subsidiaries transfer components equity retained earnings attributable total transactions owners etc owners company balance december noncontrolling interests us dollar amounts report represent translations japanese yen solely readers convenience rate us approximate exchange rate december us dollar amounts report represent translations japanese yen solely readers convenience rate us approximate exchange rate december consolidated financial statements notes consolidated financial statements refer consolidated financial statements consolidated financial statements notes consolidated financial statements refer consolidated financial statements httpswwwotsukacomenirlibraryreporthtml httpswwwotsukacomenirlibraryreporthtml otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report data section consolidated financial statements group structure overview otsuka holdings subsidiaries year ended december main operating companies consolidated statement cash flows billions yen millions us dollars cash flows operating activities profit taxes depreciation amortization expenses impairment loss reversal impairment loss share loss profit associates finance income finance costs nonoperating income expenses decrease increase inventories decrease increase trade receivables increase decrease trade payables subtotal interest dividends received interest paid income taxes paid net cash flows used operating activities otsuka pharmaceutical co ltd holistic healthcare company supporting wholebody health helping cure disease promotion everyday health cash flows investing activities keeping corporate philosophy company expanding operations along two core businesses proceeds sales property plant equipment pharmaceutical business provides breakthrough treatments patients around world nutraceutical business helps healthy people become even healthier payments acquisition property plant equipment otsuka pharmaceutical factory inc original company otsuka group leader iv solution years payments acquisition intangible assets experience intravenous solutions business japan proceeds sales redemption investments based best partner clinical nutrition management vision company creates innovative products meet variety needs pharmaceuticals medical devices oral rehydration solutions medical foods otc payments acquisition investments drugs company expanding businesses globally mainly japan asia payments acquisition subsidiaries taiho pharmaceutical co ltd pioneer oral anticancer agents japan half century decrease increase time deposits strive improve human health contribute society enriched smilesthat corporate philosophy taiho pharmaceuticals rddriven specialty pharmaceutical company specializing three fields oncology immunology allergology urology particularly field oncology taiho well known one leading net cash flows used investing activities companies japan also actively expanding global presence consumer healthcare business focused creating products help people lead life brimming love based customerfirst policy cash flows financing activities otsuka warehouse co ltd contributing peoples health worldwide field logistics since founding otsuka warehouse consistently engaging logistics pharmaceuticals food prod purchase treasury shares ucts built common distribution platform otsuka group three product areas pharmaceuticals increase decrease current borrowings food beverages daily necessities recent years company grown offer logistics services outside group proceeds noncurrent borrowings otsuka chemical co ltd creatively giving shape power materials customers future repayments noncurrent borrowings materials core operations otsuka chemical aims create products bring prosperous living dividends paid society ceaseless technological innovation main business segments hydrazine business inorganic composite materials business pharmaceutical intermediate active pharmaceutical ingredient api business company provides products global markets areas automotive electrical electronic equipment housing healthcare net cash flows used financing activities otsuka foods co ltd creating high valueadded products offer new dietary lifestyles since founding taking company begins people food begins spirit motto otsuka foods conducts businesses increase decrease cash cash equivalents areas foods beverages deliciousness safety peace mind better health spirit foods cash cash equivalents beginning period among employees continue develop company delivers products allow customers live healthy lives create new dreams foods effect exchange rate changes cash cash equivalents otsuka medical devices co ltd aiming make otsukas medical devices business unique introducing new technologies cash cash equivalents end period otsuka medical devices seeks grow medical devices business operates mainly japan china asian countries one groups core businesses future company striving spur growth us dollar amounts report represent translations japanese yen solely readers convenience rate us approximate exchange rate december bringing together groups medical device experience knowhow integrating new technology introductions new devices thereby meeting new healthcare needs consolidated financial statements notes consolidated financial statements refer consolidated financial statements httpswwwotsukacomenirlibraryreporthtml otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report data section global network corporate informationshareholder information corporate profile company organization otsuka operates december april shareholders meeting internal control department company otsuka holdings co ltd name board directors internal audit department countries regions nutraceutical business global strategy planning headquarters established july corporate planning department uk spain sweden czech republic capital billion chairman global business support department germany portugal north president finance accounting department switzerland netherlands europe america head office kandatsukasamachi chiyodaku project office belgium tokyo japan tax department france italy companies companies tokyo shinagawa grand central tower corporate service department business development department japan headquarters konan minatoku tokyo japan investor relations department telephone administration department companies president office us canada number consolidated public relations department brazil employees csr promotion department human resources department china indonesia south business description control management related activities human resource planning department south korea india asia oceania america respect companys subsidiaries affili taiwan singapore middle east ates active pharmaceutical industry nutraceutical planning department philippines turkey industry consumer products areas legal affairs department vietnam pakistan companies companies statutory auditors statutory auditors office thailand egypt companies board statutory auditors myanmar australia new zealand shares december otsuka holdings subsidiaries affiliates companies december number shares authorized shares number shares issued shares number shareholders number operations employees principal shareholders top shareholders stock distribution number share name shareholder shares holding treasury securities held ratio shares companies thousand nomura trust banking co ltd otsuka founders shareholding fund trust account companies employees factories research institutes financial master trust bank japan ltd trust account corporations institutions japan trustee services bank ltd trust account breakdown approx otsuka estate co ltd shareholders type otsuka group employee shareholding fund japan japan approx japan japan awa bank ltd outside japan outside japan approx outside japan outside japan japan trustee services bank ltd trust account state street bank west client treaty japan trustee services bank ltd trust account individuals overseas others corporations otsuka asset co ltd number shares held rounded nearest thousand history global business expansion although company holds shares treasury shares excluded list shareholding ratio calculated treasury shares deducted north america africa western china india south eastern turkey australia us egypt europe america europe website information otsuka holdings website asia thailand spain brazil czech httpswwwotsukacomen republic visit website otsuka holdings co ltd integrated report otsuka holdings co ltd integrated report significance corporate symbol symbolic representation otsuka groups corporate philosophy corporate symbol adopts initial corporate name motif representing sky large rendered grada tions otsuka blue small otsuka red represents focused energy otsuka wellspring tenets offsetting two forms poised balance otsuka name spelled open friendly typeface corporate symbol conveys otsuka groups energetic commitment human happiness good health